
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Advancements and challenges in CAR-T cell therapy for solid tumors: A comprehensive review of antigen targets, strategies, and future directions - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="15251B3F8AEEE2C3051B3F0053450790.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="cancell">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374352/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Cancer Cell International">
<meta name="citation_title" content="Advancements and challenges in CAR-T cell therapy for solid tumors: A comprehensive review of antigen targets, strategies, and future directions">
<meta name="citation_author" content="Jiajun Zhu">
<meta name="citation_author_institution" content="Department of Laboratory Medicine, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai, 200040 China">
<meta name="citation_author_institution" content="Shanghai Medical College, Fudan University, 130 Dongan Road, Shanghai, 200032 China">
<meta name="citation_author_institution" content="Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China">
<meta name="citation_author" content="Jianming Zhou">
<meta name="citation_author_institution" content="Shanghai Medical College, Fudan University, 130 Dongan Road, Shanghai, 200032 China">
<meta name="citation_author_institution" content="Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China">
<meta name="citation_author" content="Yiting Tang">
<meta name="citation_author_institution" content="Department of Laboratory Medicine, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai, 200040 China">
<meta name="citation_author_institution" content="Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China">
<meta name="citation_author" content="Ruotong Huang">
<meta name="citation_author_institution" content="Shanghai Medical College, Fudan University, 130 Dongan Road, Shanghai, 200032 China">
<meta name="citation_author_institution" content="Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China">
<meta name="citation_author" content="Chengjia Lu">
<meta name="citation_author_institution" content="Shanghai Medical College, Fudan University, 130 Dongan Road, Shanghai, 200032 China">
<meta name="citation_author_institution" content="Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China">
<meta name="citation_author" content="Ke Qian">
<meta name="citation_author_institution" content="Shanghai Medical College, Fudan University, 130 Dongan Road, Shanghai, 200032 China">
<meta name="citation_author_institution" content="Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China">
<meta name="citation_author" content="Qingyu Zhou">
<meta name="citation_author_institution" content="Shanghai Medical College, Fudan University, 130 Dongan Road, Shanghai, 200032 China">
<meta name="citation_author_institution" content="Department of Clinical Laboratory, Central Laboratory, Jing’an District Center Hospital of Shanghai, Fudan University, 259 Xikang Road, Shanghai, 200040 China">
<meta name="citation_author_institution" content="Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China">
<meta name="citation_author" content="Jingjun Zhang">
<meta name="citation_author_institution" content="Department of Clinical Laboratory, Central Laboratory, Jing’an District Center Hospital of Shanghai, Fudan University, 259 Xikang Road, Shanghai, 200040 China">
<meta name="citation_author_institution" content="Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China">
<meta name="citation_author" content="Xiaoyi Yang">
<meta name="citation_author_institution" content="Shanghai Medical College, Fudan University, 130 Dongan Road, Shanghai, 200032 China">
<meta name="citation_author_institution" content="Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China">
<meta name="citation_author" content="Wenhan Zhou">
<meta name="citation_author_institution" content="Shanghai Medical College, Fudan University, 130 Dongan Road, Shanghai, 200032 China">
<meta name="citation_author_institution" content="Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China">
<meta name="citation_author" content="Jiaqiang Wu">
<meta name="citation_author_institution" content="Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China">
<meta name="citation_author_institution" content="Department of Dermatology, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai, 200040 China">
<meta name="citation_author" content="Qiudan Chen">
<meta name="citation_author_institution" content="Department of Clinical Laboratory, Central Laboratory, Jing’an District Center Hospital of Shanghai, Fudan University, 259 Xikang Road, Shanghai, 200040 China">
<meta name="citation_author_institution" content="Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China">
<meta name="citation_author" content="Yong Lin">
<meta name="citation_author_institution" content="Department of Laboratory Medicine, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai, 200040 China">
<meta name="citation_author_institution" content="Shanghai Medical College, Fudan University, 130 Dongan Road, Shanghai, 200032 China">
<meta name="citation_author_institution" content="Department of Clinical Laboratory, Central Laboratory, Jing’an District Center Hospital of Shanghai, Fudan University, 259 Xikang Road, Shanghai, 200040 China">
<meta name="citation_author_institution" content="Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China">
<meta name="citation_author_institution" content="Department of Clinical Laboratory, Fifth People’s Hospital, Fudan University, 801 Heqing Road, Shanghai, 200240 China">
<meta name="citation_author" content="Shuying Chen">
<meta name="citation_author_institution" content="Department of Laboratory Medicine, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai, 200040 China">
<meta name="citation_author_institution" content="Shanghai Medical College, Fudan University, 130 Dongan Road, Shanghai, 200032 China">
<meta name="citation_author_institution" content="Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China">
<meta name="citation_publication_date" content="2025 Aug 23">
<meta name="citation_volume" content="25">
<meta name="citation_firstpage" content="313">
<meta name="citation_doi" content="10.1186/s12935-025-03938-0">
<meta name="citation_pmid" content="40849468">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374352/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374352/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374352/pdf/12935_2025_Article_3938.pdf">
<meta name="description" content="Chimeric antigen receptor-modified T cell therapy, originally employed in hematological malignancies treatment, has made significant strides in addressing solid tumors in recent years. Presently, second-generation CAR-T therapy has reached clinical ...">
<meta name="og:title" content="Advancements and challenges in CAR-T cell therapy for solid tumors: A comprehensive review of antigen targets, strategies, and future directions">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Chimeric antigen receptor-modified T cell therapy, originally employed in hematological malignancies treatment, has made significant strides in addressing solid tumors in recent years. Presently, second-generation CAR-T therapy has reached clinical ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374352/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12374352">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1186/s12935-025-03938-0"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/12935_2025_Article_3938.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12374352%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12374352/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12374352/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374352/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-cancell.png" alt="Cancer Cell International logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Cancer Cell International" title="Link to Cancer Cell International" shape="default" href="https://cancerci.biomedcentral.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Cancer Cell Int</button></div>. 2025 Aug 23;25:313. doi: <a href="https://doi.org/10.1186/s12935-025-03938-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1186/s12935-025-03938-0</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Cancer%20Cell%20Int%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cancer%20Cell%20Int%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Cancer%20Cell%20Int%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Cancer%20Cell%20Int%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Advancements and challenges in CAR-T cell therapy for solid tumors: A comprehensive review of antigen targets, strategies, and future directions</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhu%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Jiajun Zhu</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Jiajun Zhu</span></h3>
<div class="p">
<sup>1</sup>Department of Laboratory Medicine, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai, 200040 China </div>
<div class="p">
<sup>2</sup>Shanghai Medical College, Fudan University, 130 Dongan Road, Shanghai, 200032 China </div>
<div class="p">
<sup>4</sup>Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhu%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jiajun Zhu</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhou%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Jianming Zhou</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Jianming Zhou</span></h3>
<div class="p">
<sup>2</sup>Shanghai Medical College, Fudan University, 130 Dongan Road, Shanghai, 200032 China </div>
<div class="p">
<sup>4</sup>Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhou%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jianming Zhou</span></a>
</div>
</div>
<sup>2,</sup><sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tang%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Yiting Tang</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Yiting Tang</span></h3>
<div class="p">
<sup>1</sup>Department of Laboratory Medicine, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai, 200040 China </div>
<div class="p">
<sup>4</sup>Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tang%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yiting Tang</span></a>
</div>
</div>
<sup>1,</sup><sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Huang%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Ruotong Huang</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Ruotong Huang</span></h3>
<div class="p">
<sup>2</sup>Shanghai Medical College, Fudan University, 130 Dongan Road, Shanghai, 200032 China </div>
<div class="p">
<sup>4</sup>Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Huang%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Ruotong Huang</span></a>
</div>
</div>
<sup>2,</sup><sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lu%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Chengjia Lu</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Chengjia Lu</span></h3>
<div class="p">
<sup>2</sup>Shanghai Medical College, Fudan University, 130 Dongan Road, Shanghai, 200032 China </div>
<div class="p">
<sup>4</sup>Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lu%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Chengjia Lu</span></a>
</div>
</div>
<sup>2,</sup><sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Qian%20K%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Ke Qian</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Ke Qian</span></h3>
<div class="p">
<sup>2</sup>Shanghai Medical College, Fudan University, 130 Dongan Road, Shanghai, 200032 China </div>
<div class="p">
<sup>4</sup>Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Qian%20K%22%5BAuthor%5D" class="usa-link"><span class="name western">Ke Qian</span></a>
</div>
</div>
<sup>2,</sup><sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhou%20Q%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Qingyu Zhou</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Qingyu Zhou</span></h3>
<div class="p">
<sup>2</sup>Shanghai Medical College, Fudan University, 130 Dongan Road, Shanghai, 200032 China </div>
<div class="p">
<sup>3</sup>Department of Clinical Laboratory, Central Laboratory, Jing’an District Center Hospital of Shanghai, Fudan University, 259 Xikang Road, Shanghai, 200040 China </div>
<div class="p">
<sup>4</sup>Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhou%20Q%22%5BAuthor%5D" class="usa-link"><span class="name western">Qingyu Zhou</span></a>
</div>
</div>
<sup>2,</sup><sup>3,</sup><sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Jingjun Zhang</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Jingjun Zhang</span></h3>
<div class="p">
<sup>3</sup>Department of Clinical Laboratory, Central Laboratory, Jing’an District Center Hospital of Shanghai, Fudan University, 259 Xikang Road, Shanghai, 200040 China </div>
<div class="p">
<sup>4</sup>Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jingjun Zhang</span></a>
</div>
</div>
<sup>3,</sup><sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yang%20X%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Xiaoyi Yang</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Xiaoyi Yang</span></h3>
<div class="p">
<sup>2</sup>Shanghai Medical College, Fudan University, 130 Dongan Road, Shanghai, 200032 China </div>
<div class="p">
<sup>4</sup>Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yang%20X%22%5BAuthor%5D" class="usa-link"><span class="name western">Xiaoyi Yang</span></a>
</div>
</div>
<sup>2,</sup><sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhou%20W%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Wenhan Zhou</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Wenhan Zhou</span></h3>
<div class="p">
<sup>2</sup>Shanghai Medical College, Fudan University, 130 Dongan Road, Shanghai, 200032 China </div>
<div class="p">
<sup>4</sup>Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhou%20W%22%5BAuthor%5D" class="usa-link"><span class="name western">Wenhan Zhou</span></a>
</div>
</div>
<sup>2,</sup><sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wu%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Jiaqiang Wu</span></a><div hidden="hidden" id="id11">
<h3><span class="name western">Jiaqiang Wu</span></h3>
<div class="p">
<sup>4</sup>Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China </div>
<div class="p">
<sup>5</sup>Department of Dermatology, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai, 200040 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wu%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jiaqiang Wu</span></a>
</div>
</div>
<sup>4,</sup><sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chen%20Q%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Qiudan Chen</span></a><div hidden="hidden" id="id12">
<h3><span class="name western">Qiudan Chen</span></h3>
<div class="p">
<sup>3</sup>Department of Clinical Laboratory, Central Laboratory, Jing’an District Center Hospital of Shanghai, Fudan University, 259 Xikang Road, Shanghai, 200040 China </div>
<div class="p">
<sup>4</sup>Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chen%20Q%22%5BAuthor%5D" class="usa-link"><span class="name western">Qiudan Chen</span></a>
</div>
</div>
<sup>3,</sup><sup>4,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lin%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id13"><span class="name western">Yong Lin</span></a><div hidden="hidden" id="id13">
<h3><span class="name western">Yong Lin</span></h3>
<div class="p">
<sup>1</sup>Department of Laboratory Medicine, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai, 200040 China </div>
<div class="p">
<sup>2</sup>Shanghai Medical College, Fudan University, 130 Dongan Road, Shanghai, 200032 China </div>
<div class="p">
<sup>3</sup>Department of Clinical Laboratory, Central Laboratory, Jing’an District Center Hospital of Shanghai, Fudan University, 259 Xikang Road, Shanghai, 200040 China </div>
<div class="p">
<sup>4</sup>Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China </div>
<div class="p">
<sup>6</sup>Department of Clinical Laboratory, Fifth People’s Hospital, Fudan University, 801 Heqing Road, Shanghai, 200240 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lin%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yong Lin</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>3,</sup><sup>4,</sup><sup>6,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chen%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id14"><span class="name western">Shuying Chen</span></a><div hidden="hidden" id="id14">
<h3><span class="name western">Shuying Chen</span></h3>
<div class="p">
<sup>1</sup>Department of Laboratory Medicine, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai, 200040 China </div>
<div class="p">
<sup>2</sup>Shanghai Medical College, Fudan University, 130 Dongan Road, Shanghai, 200032 China </div>
<div class="p">
<sup>4</sup>Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chen%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Shuying Chen</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>4,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Department of Laboratory Medicine, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai, 200040 China </div>
<div id="Aff2">
<sup>2</sup>Shanghai Medical College, Fudan University, 130 Dongan Road, Shanghai, 200032 China </div>
<div id="Aff3">
<sup>3</sup>Department of Clinical Laboratory, Central Laboratory, Jing’an District Center Hospital of Shanghai, Fudan University, 259 Xikang Road, Shanghai, 200040 China </div>
<div id="Aff4">
<sup>4</sup>Department of Rehabilitation Medicine, The Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233 China </div>
<div id="Aff5">
<sup>5</sup>Department of Dermatology, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai, 200040 China </div>
<div id="Aff6">
<sup>6</sup>Department of Clinical Laboratory, Fifth People’s Hospital, Fudan University, 801 Heqing Road, Shanghai, 200240 China </div>
<div class="author-notes p"><div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Feb 9; Accepted 2025 Aug 1; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12374352  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40849468/" class="usa-link">40849468</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<p id="Par1">Chimeric antigen receptor-modified T cell therapy, originally employed in hematological malignancies treatment, has made significant strides in addressing solid tumors in recent years. Presently, second-generation CAR-T therapy has reached clinical implementation, while fifth-generation CAR-T therapy is in active development. However, initial clinical trials in solid tumors have shown limited success, primarily due to the immunosuppressive microenvironment of the tumor and the scarcity of tumor-specific antigens. Nevertheless, emerging strategies, including combination therapies and gene editing technologies, exhibit promising potential in enhancing CAR-T cell effectiveness. In this review, we comprehensively examine the current state of research on CAR-T cell therapy for solid tumors, with a particular focus on the various antigenic targets that have been explored for solid tumors. We critically review established and novel targets, providing insights into their therapeutic potential and limitations. Additionally, we highlight the key challenges that currently hinder the success of CAR-T therapy in solid tumors, including the choice of target antigens, physical barriers, antigen escape, immunosuppressive microenvironment, and adverse reactions. Despite the formidable challenges confronting CAR-T cell therapy in solid tumors, ongoing research is forging a path towards its integration into the mainstream cancer treatment paradigm, offering renewed optimism for enhanced outcomes in patients afflicted with solid malignancies.</p>
<section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> CAR-T, Solid tumor, Immunotherapy, Antigen target, Personalized treatment</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p id="Par2">Chimeric antigen receptor-modified T cell (CAR-T) therapy, a form of precision-targeted treatment for tumors, stands out as a forefront area in contemporary clinical oncology. It has emerged as one of the most extensively studied fields in recent years for the treatment of tumors. It is undoubtedly a very efficient, accurate and promising immunotherapeutic approach to treat tumors. Though it was originally employed in leukemia and lymphoma treatmen [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>, <a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>], it is now confirmed to be promising in treating solid tumors.</p>
<section id="Sec2"><h3 class="pmc_sec_title">Development of CAR-T therapy</h3>
<p id="Par3">Since 1987, Kuwana et al. first proposed the first generation of chimeric antigen receptor (CAR) by designing chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions [<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>]. Over the next 30 years, with continuous development and improvement, several generations of CAR have been constructed. In 2017, CD19 CAR-T cells received FDA approval for the treatment of leukemia and lymphoma. In 2021, Axicabtagene Ciloleucel Injection and Relmacabtagene autoleucel injection were successively approved for listing in China. The history of CAR-T is summarized in Fig. <a href="#Fig1" class="usa-link">1</a>. So far, CAR-T cell therapy have played a significant role in B-cell malignancies, revolutionizing the field of tumor immunotherapy. However, Early attempts of second-generation CAR-T technology in solid tumors have met with setbacks, and most of the related drugs for CAR-T treatment in solid tumors are still under development [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>]. </p>
<figure class="fig xbox font-sm" id="Fig1"><h4 class="obj_head">Fig. 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374352_12935_2025_3938_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f185/12374352/b8940240a6f0/12935_2025_3938_Fig1_HTML.jpg" loading="lazy" id="d33e313" height="153" width="669" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Key events in the history of CAR-T therapy</p></figcaption></figure></section><section id="Sec3"><h3 class="pmc_sec_title">The five generations of CAR-T therapy</h3>
<p id="Par5">Up to now, CAR-T therapy has experienced five generations of drug development and has made remarkable progress in Fig. <a href="#Fig2" class="usa-link">2</a>. The first generation of CAR-T technology contained only one intracellular signaling domain (CD3ζ) [<a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>]. The development of the second and third generations of CAR-T involved the incorporation of one or two co-stimulatory signal domains (such as CD28, OX40, and 4-1BB) to the first-generation CAR, respectively [<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>–<a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>]. The fourth generation of CAR (TRUCKs)is to further introduce functional cytokines to enhance the killing and expansion ability of T cells [<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>]. The fifth generation of CAR enhances the intracellular domain of the cytokine receptor (IL-2Rβ) on the basis of the second generation, further enhancing cell proliferation and activation [<a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>, <a href="#CR10" class="usa-link" aria-describedby="CR10">10</a>]. It can be seen that since the advent of the fourth generation of CAR-T, researches have gradually focused on giving this therapy a wider range of anti-tumor capabilities, so that it can be applied to the treatment of various solid tumors. With the development of each generation of CAR-T therapy, the potential of CAR-T in the treatment of solid tumors is becoming more evident.</p>
<figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374352_12935_2025_3938_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f185/12374352/6ff825594c3e/12935_2025_3938_Fig2_HTML.jpg" loading="lazy" id="d33e349" height="306" width="669" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Five generations of CAR. This figure provides a detailed comparison of the five generations of CAR-T therapy. It shows the progression from the first-generation CAR with a single CD3ζ signaling domain to the second and third generations incorporating co-stimulatory signals (e.g., CD28, 4-1BB) for enhanced T cell activation and proliferation. The fourth generation (TRUCKs) introduces cytokine secretion to further boost antitumor effects, while the fifth generation enhances intracellular signaling through cytokine receptors (e.g., IL-2Rβ) to improve cell function. The figure also depicts how each generation performs upon encountering target antigens, highlighting differences in activation, proliferation, and cytotoxic capabilities</p></figcaption></figure></section><section id="Sec4"><h3 class="pmc_sec_title">Common antigen targets in solid tumors</h3>
<p id="Par7">The anti-solid tumor mechanism of CAR-T cells is similar to that of non-solid tumor (Fig. <a href="#Fig3" class="usa-link">3</a>), but they face completely different situations. Over the past few years, notable progress has been made in CAR-T therapy treating solid tumors. Following the achievement of a successful binding to the CD19 target in B cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma, researchers have also identified more effective binding targets in solid tumors. With the development of sequencing techniques, a variety of characteristic solid tumor targets are being discovered. Common solid tumor targets include MSLN, GPC3, GD2, HER2, CEA, DLL3, BCMA, GUCY2C, EGFR, NKG2DL and so on. Corresponding CAR-T therapy drugs targeting some of the receptors listed in Table <a href="#Tab1" class="usa-link">1</a> have already entered preclinical and clinical trials. The following section will provide a detailed overview of the latest studies based on different targets.</p>
<figure class="fig xbox font-sm" id="Fig3"><h4 class="obj_head">Fig. 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374352_12935_2025_3938_Fig3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f185/12374352/29aefd203bd6/12935_2025_3938_Fig3_HTML.jpg" loading="lazy" id="d33e382" height="440" width="669" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>This figure illustrates the comprehensive mechanism of CAR-T cell therapy. Panel (<strong>A</strong>) shows the in vitro culture process, where T cells are extracted from the patient, genetically modified to express chimeric antigen receptors (CARs), and expanded in the laboratory to achieve a sufficient number for infusion. Panel (<strong>B</strong>) depicts how these engineered CAR-T cells travel through the bloodstream and specifically recognize tumor antigens on cancer cells, enabling them to localize to the tumor site. Panel (<strong>C</strong>) details the interaction between CAR-T cells and tumor cells, where the binding of the CAR to the target antigen activates the T cell, leading to the release of cytotoxic granules that induce apoptosis in the tumor cell. Finally, panel (<strong>D</strong>) highlights the broader immune response, where activated CAR-T cells recruit additional immune cells, participate in antigen presentation, and enhance the overall antitumor effect through collaborative immune activity</p></figcaption></figure><section class="tw xbox font-sm" id="Tab1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Common target antigens of solid tumors</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Tissues</th>
<th align="left" colspan="1" rowspan="1">Targeted antigens</th>
<th align="left" colspan="1" rowspan="1">Investigational Stage</th>
</tr></thead>
<tbody>
<tr>
<td align="left" rowspan="4" colspan="1">Neural</td>
<td align="left" colspan="1" rowspan="1">GD2 [<a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase II/III</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">L1CAM [<a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>]</td>
<td align="left" colspan="1" rowspan="1">Preclinical</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PHOX2B [<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a>]</td>
<td align="left" colspan="1" rowspan="1">Preclinical</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CAIX [<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase I/II</td>
</tr>
<tr>
<td align="left" rowspan="3" colspan="1">Brain</td>
<td align="left" colspan="1" rowspan="1">EGFR VIII [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase II/III</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">HER2 [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase I/II</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">IL13RA [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase I/II</td>
</tr>
<tr>
<td align="left" rowspan="6" colspan="1">Lung</td>
<td align="left" colspan="1" rowspan="1">CEA [<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase I/II</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">EGFR [<a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase III/IV</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">HER2 [<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase I/II</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">MSLN [<a href="#CR20" class="usa-link" aria-describedby="CR20">20</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase II/III</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">EPCAM [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>]</td>
<td align="left" colspan="1" rowspan="1">Preclinical</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CDH17 [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]</td>
<td align="left" colspan="1" rowspan="1">Preclinical</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Liver</td>
<td align="left" colspan="1" rowspan="1">GPC3 [<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>, <a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase I/II</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CEA [<a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase I/II</td>
</tr>
<tr>
<td align="left" rowspan="5" colspan="1">Colorectum</td>
<td align="left" colspan="1" rowspan="1">CEA [<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase I/II</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CDH17 [<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>]</td>
<td align="left" colspan="1" rowspan="1">Preclinical</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GUCY2C [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase I/II</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CD44V6 [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>]</td>
<td align="left" colspan="1" rowspan="1">Preclinical</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">NKG2D [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>]</td>
<td align="left" colspan="1" rowspan="1">Preclinical</td>
</tr>
<tr>
<td align="left" rowspan="4" colspan="1">Gastric</td>
<td align="left" colspan="1" rowspan="1">CEA [<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase I/II</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">HER2 [<a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase I/II</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CLDN18.2 [<a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase II/III</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">MSLN [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase II/III</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Renal</td>
<td align="left" colspan="1" rowspan="1">VEGFR2 [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase I/II</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CAIX [<a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>, <a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase I/II</td>
</tr>
<tr>
<td align="left" rowspan="6" colspan="1">Ovarian</td>
<td align="left" colspan="1" rowspan="1">FRα [<a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>, <a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase I/II</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CEA [<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase I/II</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">HER2 [<a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase I/II</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">MSLN [<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase II/III</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">L1CAM [<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>]</td>
<td align="left" colspan="1" rowspan="1">Preclinical</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">MUC16[<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase I/II</td>
</tr>
<tr>
<td align="left" rowspan="4" colspan="1">Pancreas</td>
<td align="left" colspan="1" rowspan="1">CEA</td>
<td align="left" colspan="1" rowspan="1">Phase I/II</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">MSLN [<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>, <a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase II/III</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">MUC1 [<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>]</td>
<td align="left" colspan="1" rowspan="1">Preclinical</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CLDN18.2 [<a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase II/III</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Prostate</td>
<td align="left" colspan="1" rowspan="1">PSMA [<a href="#CR44" class="usa-link" aria-describedby="CR44">44</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase I/II</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PSCA [<a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>]</td>
<td align="left" colspan="1" rowspan="1">Preclinical</td>
</tr>
<tr>
<td align="left" rowspan="5" colspan="1">Breast</td>
<td align="left" colspan="1" rowspan="1">CEA [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase I/II</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">cMET [<a href="#CR47" class="usa-link" aria-describedby="CR47">47</a>]</td>
<td align="left" colspan="1" rowspan="1">Preclinical</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">HER2 [<a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase I/II</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">MSLN [<a href="#CR49" class="usa-link" aria-describedby="CR49">49</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase II/III</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">MUC1 [<a href="#CR50" class="usa-link" aria-describedby="CR50">50</a>]</td>
<td align="left" colspan="1" rowspan="1">Preclinical</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Skin</td>
<td align="left" colspan="1" rowspan="1">GD2 [<a href="#CR51" class="usa-link" aria-describedby="CR51">51</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase II/III</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">VEGFR [<a href="#CR51" class="usa-link" aria-describedby="CR51">51</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase I/II</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Soft tissue</td>
<td align="left" colspan="1" rowspan="1">GD2 [<a href="#CR52" class="usa-link" aria-describedby="CR52">52</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase II/III</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">HER2 [<a href="#CR53" class="usa-link" aria-describedby="CR53">53</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase I/II</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Head and neck</td>
<td align="left" colspan="1" rowspan="1">ERBB family [<a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>]</td>
<td align="left" colspan="1" rowspan="1">Phase I/II</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section></section><section id="Sec5"><h3 class="pmc_sec_title">Mesothelin (MSLN)</h3>
<p id="Par10">MSLN functions as a glycoprotein on the cell surface, which is widely expressed in tumors such as malignant pleural mesothelioma [<a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>], pancreatic cancer [<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>], ovarian cancer [<a href="#CR56" class="usa-link" aria-describedby="CR56">56</a>], some lung cancer and so on. Elevated MSLN expression intricately modulates multiple cellular signaling pathways and is strongly associated with tumor proliferation, invasion, and unfavorable prognosis (Fig. <a href="#Fig4" class="usa-link">4</a>A) [<a href="#CR57" class="usa-link" aria-describedby="CR57">57</a>]. In 2019, Zhang et al. identified that region III of MSLN targeted CAR-T cells mediated strong antitumor responses in the gastric cancer NSG mice model and effectively reduced the in vivo growth of large ovarian tumors [<a href="#CR58" class="usa-link" aria-describedby="CR58">58</a>]. In 2023, Schoutrop et al. assessed two traditional second-generation MSLN-CAR T cell designs through preclinical in vitro and in vivo models of ovarian cancer. Their investigation demonstrated that precisely modulating the activation of MSLN-CAR T cells resulted in enhanced and superior antitumor responses within the context of ovarian cancer models [<a href="#CR59" class="usa-link" aria-describedby="CR59">59</a>]. Meanwhile, several methods to enhance therapeutic effect of MSLN targeted CAR-T cells have been discovered these years. A recent study proves that Irinotecan can significantly augment the antitumor efficacy of MSLN-targeted CAR T cells, offering a promising strategy for combination therapy in MSLN-positive solid tumors [<a href="#CR60" class="usa-link" aria-describedby="CR60">60</a>]. However, in 2022, Chen et al. conducted an investigator-initiated clinical study to evaluate the safety and efficacy of anti-MSLN CAR-T cell therapy in patients with ovarian cancer. This study evaluates anti-MSLN CAR-T therapy for ovarian cancer. Preclinical models reveal strong antitumor activity. A phase I trial on three patients shows tolerability and efficacy, with one achieving stable disease and another a partial response [<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>]. </p>
<figure class="fig xbox font-sm" id="Fig4"><h4 class="obj_head">Fig. 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374352_12935_2025_3938_Fig4_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f185/12374352/0a769863547f/12935_2025_3938_Fig4_HTML.jpg" loading="lazy" id="d33e985" height="410" width="669" alt="Fig. 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>The therapeutic principle and process of CAR-T cells. <strong>(A)</strong> Putative roles of MSLN in PDAC progression [<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>]. Copyright 2020 by the authors. Licensee MDPI, Basel, Switzerland. <strong>(B)</strong> Proposed working model of sGPC3 in GPC3- specific CAR-T cell therapy [<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>]. Reproduced with permission. Copyright 2021, BMJ Publishing Group Ltd &amp; Society for Immunotherapy of Cancer. <strong>(C)</strong> GD2-4-1BB-CD3ΖCAR schematic.TM, transmembrane domain [<a href="#CR64" class="usa-link" aria-describedby="CR64">64</a>]. <strong>D</strong> Outline of clinical trial design [<a href="#CR64" class="usa-link" aria-describedby="CR64">64</a>]. Copyright 2022 The Authors. Licensee CC BY 4.0. All these figures are not modified</p></figcaption></figure></section><section id="Sec6"><h3 class="pmc_sec_title">Glypican-3(GPC3)</h3>
<p id="Par11">GPC3, a glycoprotein present on the surface of the cell, exhibits elevated pathological expression in hepatocellular carcinoma (HCC). Despite this, conventional GPC3-targeted CAR-T therapies have demonstrated efficacy in only a limited subset of HCC patients. In 2020, Sun et al. developed two variants of CAR-T cells, each targeting distinct epitopes of GPC3. Their study demonstrated that the presence of sGPC3 significantly impeded cytokine release and the cytotoxicity of anti-GPC3 CAR-T cells in vitro, unveiling a novel mechanism of immune evasion in HCC(Fig. <a href="#Fig4" class="usa-link">4</a>B) [<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>]. Ma et al. confirmed the enhanced targeting capability of CAR-T cell membrane-coated nanoparticles in comparison to mesoporous silica nanoparticles loaded with IR780, both in vitro and in vivo. This implies a potential and encouraging approach for HCC treatment [<a href="#CR61" class="usa-link" aria-describedby="CR61">61</a>]. In 2023, A study demonstrated that modifying the hinge and transmembrane domains of a nanobody-based CAR, designed to target a remote GPC3 epitope, triggered potent T-cell signaling. This adaptation resulted in prompt and enduring elimination of HCC [<a href="#CR62" class="usa-link" aria-describedby="CR62">62</a>]. In 2024, Zhang Qi et al. reported the safety and anti-tumor activity of C-CAR031, an autologous CAR-T cell therapy targeting GPC3, in 24 patients receiving intravenous infusion. Among the 22 patients evaluated for efficacy, 90.9% experienced tumor shrinkage, with improvements in both intrahepatic and extrahepatic lesions, and a median reduction rate of 44.0%. The disease control rate across all cohorts was 90.9%, with an overall response rate (ORR) of 50.0%. In the DL4 cohort, the ORR was 57.1%. No dose-limiting toxicities or ICANS were observed, and low-grade CRS was noted in 22 patients [<a href="#CR63" class="usa-link" aria-describedby="CR63">63</a>].</p></section><section id="Sec7"><h3 class="pmc_sec_title">Disialoganglioside 2(GD2)</h3>
<p id="Par12">GD2 is a specific target for neuroblastoma immunotherapy. Several studies are currently underway in clinical trials. In 2020, Michelle Monje’s team from Stanford University initiated a phase 1–2 clinical trial which aimed to evaluate the feasibility and safety of GD2-CART01, a third-generation GD2-CAR-T cell therapy expressing the inducible caspase 9 suicide gene, in patients experiencing relapsed or refractory high-risk neuroblastoma [<a href="#CR64" class="usa-link" aria-describedby="CR64">64</a>]. In 2022, first-in-human phase I clinical trial involving GD2-CAR-T cells for the treatment of H3K27M-mutated diffuse intrinsic pontine glioma (DIPG) or spinal cord diffuse midline glioma (DMG) showed notable efficacy, among the four patients enrolled, three exhibited improvements both clinically and radiographically. This positive outcome was attributed to elevated levels of pro-inflammatory cytokines in both the plasma and cerebrospinal fluid (Fig. <a href="#Fig4" class="usa-link">4</a>C and D) [<a href="#CR64" class="usa-link" aria-describedby="CR64">64</a>]. In 2023, Francesca Del Bufalo et al. released the clinical trial data for GD2-CART01 in the treatment of relapsed or refractory high-risk neuroblastoma. Six weeks after GD2-CART01 infusion, 9 out of 27 patients (33%) achieved a complete response (8 patients) or sustained a previously achieved complete response (1 patient) [<a href="#CR64" class="usa-link" aria-describedby="CR64">64</a>]. Research on combination therapy is also making progress. In 2023, a study indicated that administering a high dosage of GD2 CAR-T induced tumor apoptosis via the p53/caspase-3/PARP signaling pathway. This suggests that combining GD2 CAR-T with Nivolumab could present an enhanced therapeutic approach for glioblastoma treatment [<a href="#CR65" class="usa-link" aria-describedby="CR65">65</a>]. A phase 1–2 clinical trial conducted by Quintarelli, C, et al. investigated the efficacy of GD2-CART01 treatment in 27 pediatric neuroblastoma patients who had undergone multiple prior therapies. Within 30 months post-treatment, the overall response rate was 63% (17/27), which thus far constitutes the most promising data generated using CAR-T in the solid tumor setting., suggesting the safety and feasibility of GD2-CART01 therapy for high-risk neuroblastoma and the possibility of a prolonged anti-tumor effect [<a href="#CR66" class="usa-link" aria-describedby="CR66">66</a>].</p></section><section id="Sec8"><h3 class="pmc_sec_title">Human epidermal growth factor receptor 2(HER2)</h3>
<p id="Par14">HER2 is a member of the transmembrane epidermal growth factor receptor family, standing out as one of the extensively investigated tumor-associated antigens in the realm of cancer immunotherapy. It is frequently regarded as a specific target for ovarian and breast cancer (Fig. <a href="#Fig5" class="usa-link">5</a>A) [<a href="#CR67" class="usa-link" aria-describedby="CR67">67</a>]. Research has demonstrated that HER2-CAR-T exhibits specific recognition of HER2-positive tumor cells, effectively inhibiting tumor growth both in vivo and in vitro. Furthermore, the therapeutic efficacy of HER2-CAR-T on tumors is significantly enhanced by anti-PDL1 treatment [<a href="#CR68" class="usa-link" aria-describedby="CR68">68</a>]. Another study highlighted that inhibiting PD1-mediated immuno-suppression can enhance the activation of CAR-T cells once they are activated by a targeting antigen, while third generation anti-HER2 CAR-T cells in combination with PD1 blockade showed considerable promise in treating malignant glioblastoma [<a href="#CR69" class="usa-link" aria-describedby="CR69">69</a>]. In 2020, Baylor College conducted clinical trials involving the infusion of autologous HER2 CAR-T cells for pediatric patients with refractory metastatic alveolar rhabdomyosarcoma. Following initial remission and subsequent relapse, patients underwent additional CAR-T cell reinfusion in combination with the PD-1 antibody pembrolizumab. Remarkably, they achieved complete recovery and remained relapse-free for the following 20 months, suggesting the effectiveness of CAR-T therapy for HER2-positive solid tumors [<a href="#CR70" class="usa-link" aria-describedby="CR70">70</a>]. In a phase I clinical study published in 2024, researchers investigated the safety and efficacy of HER2 CAR-T cell therapy in patients with advanced sarcoma. The trial included 14 eligible patients with HER2-overexpressing sarcomas. Among the treated patients, 50% experienced clinical benefit, with one osteosarcoma patient achieving complete remission (CR) after multiple CAR-T cell infusions, with the remission lasting over six years. Of the 12 patients, 9 experienced grade 1–2 cytokine release syndrome [<a href="#CR71" class="usa-link" aria-describedby="CR71">71</a>].</p>
<figure class="fig xbox font-sm" id="Fig5"><h4 class="obj_head">Fig. 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374352_12935_2025_3938_Fig5_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f185/12374352/d19b3040d3c5/12935_2025_3938_Fig5_HTML.jpg" loading="lazy" id="d33e1076" height="208" width="669" alt="Fig. 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Structures of the CARs mentioned above. <strong>(A)</strong> Diagram of the HER2-specific CAR, consisting of a humanized chA21 single-chain variable fragment (scFv) linked to CD28 and CD3z signaling moieties [<a href="#CR67" class="usa-link" aria-describedby="CR67">67</a>]. Reproduced with permission. Copyright 2014, Sun et al.; licensee BioMed Central Ltd. <strong>(B)</strong> Structures of the 4 CEA-specific CARs with the corresponding scFvs [<a href="#CR84" class="usa-link" aria-describedby="CR84">84</a>]. Copyright 2023, by the authors, licensee CC BY 4.0. <strong>(C)</strong> Schematic of extracellular DLL3 domains with binding location of anti-DLL3 SC16 antibody clones (top), and schematic of CAR design for initial selection of single-chain variable fragments (bottom) [<a href="#CR76" class="usa-link" aria-describedby="CR76">76</a>]. Copyright 2023, Jaspers et al. Licensee CC BY 4.0. All these figures are not modified</p></figcaption></figure></section><section id="Sec9"><h3 class="pmc_sec_title">Carcinoembryonic antigen (CEA)</h3>
<p id="Par15">CEA is associated with poor cancer prognosis and is targeted for the treatment of breast, lung, colorectal, gastric and pancreatic cancers [<a href="#CR72" class="usa-link" aria-describedby="CR72">72</a>]. In 2019, Chi et al. engineered CAR-T cells specific to CEA and employed them in conjunction with recombinant human IL-12 (rhIL-12) for the treatment of various solid tumors. Their findings confirmed that the concurrent use of cytokines such as rhIL-12 enhances the anti-tumor activity of CAR-T cells [<a href="#CR72" class="usa-link" aria-describedby="CR72">72</a>]. In 2023, Zhang et al. conducted a comparison of four humanized or fully human anti-CEA antibodies (C2-45, BW431/26, hMN-14, and M5A) utilizing a 3rd-generation CAR structure. Among these, M5A exhibited the highest levels of cell proliferation and cytokine secretion (Fig. <a href="#Fig5" class="usa-link">5</a>B) [<a href="#CR73" class="usa-link" aria-describedby="CR73">73</a>]. Sato et al. assessed the correlation between the expression level of CEA and the antitumor efficacy of anti-CEA-CAR-T through a functional assay involving various pancreatic ductal adenocarcinoma (PDAC) cell lines and proved the correlation between tumor heterogeneity and the intensity of CEA immunostaining. Therefore, CEA expression levels can serve as clinically relevant biomarkers for the selection of PDAC patients eligible for anti-CAR-T therapy [<a href="#CR74" class="usa-link" aria-describedby="CR74">74</a>].</p></section><section id="Sec10"><h3 class="pmc_sec_title">Delta-like ligand 3(DLL3)</h3>
<p id="Par16">DLL3 has been identified as a distinctive cell surface marker exclusive to neuroendocrine cancers, observed in small cell lung cancer (SCLC) [<a href="#CR74" class="usa-link" aria-describedby="CR74">74</a>]. Zhang et al. proved that infusing DLL3 CAR-T cells exhibited strong anti-tumor efficacy, resulting in complete responses, in both subcutaneous and systemic in vivo models of SCLC [<a href="#CR75" class="usa-link" aria-describedby="CR75">75</a>]. In vivo experiments on mice also demonstrated that the production of IL-18 significantly enhanced the activation of CAR-T cells, antigen-presenting cells and endogenous tumor-infiltrating lymphocytes thus greatly enhancing the effectiveness of DLL3-targeting CAR T cell therapy (Fig. <a href="#Fig5" class="usa-link">5</a>C) [<a href="#CR76" class="usa-link" aria-describedby="CR76">76</a>]. In 2023, Zhou et al. reported the clinical pharmacology profile of AMG119, the pioneering CAR-T cell therapy targeting DLL3, in individuals with relapsed/refractory (R/R) SCLC and obtained encouraging cellular kinetics data [<a href="#CR77" class="usa-link" aria-describedby="CR77">77</a>], bringing hope for the drug to market. Other CAR-T therapies in development include ALLO-213 and LB-2102.</p></section><section id="Sec11"><h3 class="pmc_sec_title">Guanylyl cyclase C(GUCY2C)</h3>
<p id="Par18">GUCY2C serves as a versatile biomarker and distinctive CAR-T therapeutic target for colorectal cancer [<a href="#CR78" class="usa-link" aria-describedby="CR78">78</a>]. Research shows the potential of human GUCY2C-targeted CAR-T cells eliminating colorectal cancer metastases [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>]. In vitro experiments demonstrated that CAR-T cells targeting human GUCY2C exhibit a selective capacity to eliminate colorectal cancer cells expressing GUCY2C, concurrently inducing the production of inflammatory cytokines upon antigenic stimulation [<a href="#CR79" class="usa-link" aria-describedby="CR79">79</a>]. In 2024, Qi Changsong et al. reported a phase I clinical trial of CAR-T therapy for GUCY2C-positive metastatic colorectal cancer (mCRC). Among 19 evaluable patients, the disease control rate (DCR) was 73.7%, and the overall response rate (ORR) was 26.3%. In the DL3 cohort, the ORR was 40%, with a median progression-free survival (PFS) of 7 months and a median response duration of 10 months. A reduction in carcinoembryonic antigen levels correlated with tumor response [<a href="#CR80" class="usa-link" aria-describedby="CR80">80</a>]. Recently, Naifei Chen and colleagues published clinical study results of GCC19CART in metastatic colorectal cancer, showing an objective response rate (ORR) of 40% and a median overall survival (mOS) of 22.8 months. Responding patients had an approximately 75% chance of survival two years later [<a href="#CR81" class="usa-link" aria-describedby="CR81">81</a>].</p></section><section id="Sec12"><h3 class="pmc_sec_title">Epidermal growth factor receptor (EGFR)</h3>
<p id="Par19">EGFR is closely associated with the development and advancement of solid tumors, establishing itself as a crucial therapeutic target, particularly in non-small-cell lung carcinoma (NSCLC), glioblastoma, colorectal, breast, gastroesophageal cancers and so on [<a href="#CR82" class="usa-link" aria-describedby="CR82">82</a>]. In 2021, Li et al. designed an EGFR CAR-T cell that incorporates a second receptor, CXCR5, with the aim of promoting the migration of CAR-T cells towards NSCLC tumors expressing CXCL13. This innovative approach suggests a novel method for enhancing T cell infiltration to the tumor site (Fig. <a href="#Fig6" class="usa-link">6</a>A and B) [<a href="#CR83" class="usa-link" aria-describedby="CR83">83</a>]. In 2023, Li et al. demonstrated the effectiveness of TGF-β signaling-resistant EGFR-targeted CAR-T cells, achieved through SMAD7 overexpression specifically confined to the CAR-T cells themselves. EGFR-SMAD7-CAR-T cells exhibited an elevated proliferation rate and enhanced lysis capacity against carcinoma cells [<a href="#CR84" class="usa-link" aria-describedby="CR84">84</a>].</p>
<figure class="fig xbox font-sm" id="Fig6"><h4 class="obj_head">Fig. 6.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374352_12935_2025_3938_Fig6_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f185/12374352/c8215522e283/12935_2025_3938_Fig6_HTML.jpg" loading="lazy" id="d33e1159" height="235" width="669" alt="Fig. 6"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig6/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Mechanism of action of CAR-T cells and structure of CARs. <strong>(A)</strong> The motorized CAR-T cells could infiltrate into the tumor site along the gradient of CXCL13 to further clear the tumor cells when CAR-T cells are modified with the CXCR5 receptor [<a href="#CR83" class="usa-link" aria-describedby="CR83">83</a>]. Copyright 2021 The Authors. <strong>(B)</strong> Graphical representation of the CAR designed using the anti-EGFR scFv, CD8a hinge, and transmembrane domain, 4-1BB and CD3zeta endodomain [<a href="#CR83" class="usa-link" aria-describedby="CR83">83</a>]. Reproduced with permission. Copyright 2021 The Authors. (<strong>C)</strong> Schematic illustration of a lentiviral vector encoding CARs [<a href="#CR83" class="usa-link" aria-describedby="CR83">83</a>]. Copyright 2021 The Authors. All these figures are not modified</p></figcaption></figure><p id="Par20">In addition, there are a number of dual-target and multi-target CAR-T therapies under research, such as c-Met/PD-L1 CAR-T cells for treating HCC(Fig. <a href="#Fig6" class="usa-link">6</a>C) [<a href="#CR85" class="usa-link" aria-describedby="CR85">85</a>], co-express GPC3 with EGFR-targeted CAR-T treating HCC [<a href="#CR86" class="usa-link" aria-describedby="CR86">86</a>] Her2/B7H3 CAR-T cells treating CNS tumors [<a href="#CR87" class="usa-link" aria-describedby="CR87">87</a>] and so on. A multiple-target CAR-T cell therapy approach can enhance anti-tumor efficacy and mitigate the risk of relapse attributed to antigen loss [<a href="#CR88" class="usa-link" aria-describedby="CR88">88</a>]. Currently, several CAR-T drugs are undergoing clinical test both domestically and internationally.</p></section><section id="Sec13"><h3 class="pmc_sec_title">Claudin18.2 (CLDN18.2)</h3>
<p id="Par22">Claudin18.2 is highly expressed in multiple cancers such as lung mucinous adenocarcinoma, colorectal adenocarcinoma, and cervical adenocarcinoma [<a href="#CR89" class="usa-link" aria-describedby="CR89">89</a>], positioning it as a promising target for anti-tumor therapy. CT041 is a global first-in-class autologous CAR-T cell candidate product targeting Claudin18.2, designed for the treatment of Claudin18.2-positive solid tumors. It is primarily used for the treatment of gastric cancer [<a href="#CR90" class="usa-link" aria-describedby="CR90">90</a>] or pancreatic cancer [<a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>]. In 2024, an analysis of two phase I/Ib clinical trials for the treatment of pancreatic cancer with CT041, conducted by the research team at Peking University Cancer Hospital, showed that among the 24 pancreatic cancer patients enrolled, 12 showed tumor target lesion shrinkage. The disease control rate (DCR) was 70.8%, with a median overall survival (mOS) of 10.0 months, a 1-year survival rate of 45.8%, a median duration of response (DOR) of 9.5 months, and a 1-year DOR rate of 50% [<a href="#CR91" class="usa-link" aria-describedby="CR91">91</a>]. In the same year, Qi et al. published the final results of a phase I clinical trial on CT041 for patients with Claudin18.2-positive advanced gastrointestinal tumors. Among the 98 patients, 70 exhibited varying degrees of tumor regression. In 51 patients with gastric cancer or gastroesophageal junction adenocarcinoma who had target lesions and were treated with CT041 monotherapy, the overall response rate (ORR) and disease control rate (DCR) were 54.9% (28/51) and 96.1% (49/51), respectively, with a median duration of response (mDOR) of 6.4 months. Among all gastric cancer/gastroesophageal junction adenocarcinoma patients receiving CT041 monotherapy (<em>n</em> = 59), the median progression-free survival (mPFS) was 5.8 months, and the median overall survival (mOS) was 9.0 months, with a 12-month survival rate of 37.3% [<a href="#CR92" class="usa-link" aria-describedby="CR92">92</a>].</p></section><section id="Sec14"><h3 class="pmc_sec_title">Novel antigen targets in CAR-T therapy for solid tumors</h3>
<section id="Sec15"><h4 class="pmc_sec_title">CS1 (SLAMF7)</h4>
<p id="Par23">CS1 is highly expressed in multiple myeloma (MM) and has demonstrated significant antitumor activity in preclinical models. It is currently being explored in clinical trials for MM. The advantages of targeting CS1 include effective reduction of tumor burden and prolonged survival in xenograft models [<a href="#CR93" class="usa-link" aria-describedby="CR93">93</a>]. However, there are several disadvantages associated with CS1-targeted CAR-T therapy. These include the potential for cytokine release syndrome (CRS), viral infections, and fratricide of normal lymphocytes, which can reduce the overall efficacy of the treatment. Additionally, the expression of CS1 on normal immune cells, such as CD8 + T cells and NK cells, poses a risk of “on-target, off-tumor” toxicity, potentially leading to prolonged immunodeficiency [<a href="#CR94" class="usa-link" aria-describedby="CR94">94</a>].</p></section><section id="Sec16"><h4 class="pmc_sec_title">TEM8/ANTXR1</h4>
<p id="Par24">TEM8/ANTXR1 has been investigated as a therapeutic target in various cancers, including gastric adenocarcinoma, showing promising preclinical results. The advantages of targeting TEM8/ANTXR1 include its overexpression in tumor-associated endothelial cells and certain tumor cells, which can potentially enhance the specificity of treatments towards tumor tissues. However, there are also disadvantages. One major concern is the potential for off-target effects, as TEM8/ANTXR1 is also expressed in healthy tissues, which may lead to toxicity and other adverse effects, as demonstrated in some in vivo studies [<a href="#CR95" class="usa-link" aria-describedby="CR95">95</a>].</p></section><section id="Sec17"><h4 class="pmc_sec_title">Glycoforms of antigens</h4>
<p id="Par25">Recent studies have delved into the glycoforms of antigens, with a particular focus on the cancer-associated Tn glycoform of MUC1. This glycoform is aberrantly expressed in a variety of cancers but is virtually absent on the surface of normal tissues. The research has demonstrated that CAR T cells engineered to target this specific glycoform exhibit robust anti-tumor activity in preclinical models of leukemia and pancreatic cancer, with minimal off-target effects. This highlights the potential of targeting unique glycosylation patterns as a novel and effective strategy in CAR-T therapy, offering a promising direction for the development of more specific and safer cancer treatments [<a href="#CR96" class="usa-link" aria-describedby="CR96">96</a>]. Another study shows that the cancer-associated Tn, T, and sialyl-Tn glycoforms of antigens such as MUC1 and CEACAM5. These aberrantly glycosylated forms are uniquely expressed on tumor cells but are virtually absent on the surface of normal tissues Table <a href="#Tab2" class="usa-link">2</a>. CAR T cells engineered to target these specific glycoforms exhibit robust anti-tumor activity in preclinical models of various cancers, including leukemia, pancreatic cancer, and breast cancer, with minimal off-target effects Table <a href="#Tab3" class="usa-link">3</a>. This focus on unique glycosylation patterns represents a novel and promising direction in CAR-T therapy, potentially offering a safer and more effective approach to treating solid tumors [<a href="#CR97" class="usa-link" aria-describedby="CR97">97</a>].</p>
<section class="tw xbox font-sm" id="Tab2"><h5 class="obj_head">Table 2.</h5>
<div class="caption p"><p>Comprehensive clinical evaluation and pros and cons of antigen targets in CAR-T therapy for solid tumors</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Antigen Target</th>
<th align="left" colspan="1" rowspan="1">Clinical Evaluation</th>
<th align="left" colspan="1" rowspan="1">Advantages</th>
<th align="left" colspan="1" rowspan="1">Disadvantages</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">GPC3</td>
<td align="left" colspan="1" rowspan="1">Highly expressed in HCC with immune evasion issues</td>
<td align="left" colspan="1" rowspan="1">Good antitumor activity and high disease control rate</td>
<td align="left" colspan="1" rowspan="1">Ineffective in some patients, immune escape</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GD2</td>
<td align="left" colspan="1" rowspan="1">Specific target for neuroblastoma and other neuroendocrine tumors</td>
<td align="left" colspan="1" rowspan="1">Good tolerability, long-term remission in some patients</td>
<td align="left" colspan="1" rowspan="1">CRS and other side effects</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">HER2</td>
<td align="left" colspan="1" rowspan="1">Highly expressed in ovarian cancer, breast cancer, and other tumors</td>
<td align="left" colspan="1" rowspan="1">Good antitumor activity</td>
<td align="left" colspan="1" rowspan="1">CRS and other side effects, potential toxicity to normal tissues</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CEA</td>
<td align="left" colspan="1" rowspan="1">Associated with poor prognosis in various cancers</td>
<td align="left" colspan="1" rowspan="1">Good antitumor activity</td>
<td align="left" colspan="1" rowspan="1">“On-target, off-tumor” toxicity, ineffective in some patients</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">DLL3</td>
<td align="left" colspan="1" rowspan="1">Specific cell surface marker for small cell lung cancer (SCLC)</td>
<td align="left" colspan="1" rowspan="1">Promising antitumor effects in preclinical studies</td>
<td align="left" colspan="1" rowspan="1">Limited clinical trial data</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GUCY2C</td>
<td align="left" colspan="1" rowspan="1">Serves as a biomarker and therapeutic target for colorectal cancer</td>
<td align="left" colspan="1" rowspan="1">CAR-T therapy shows disease control rate and objective response rate in clinical trials</td>
<td align="left" colspan="1" rowspan="1">Limited clinical data, need for further studies to confirm long-term effects and safety</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">EGFR</td>
<td align="left" colspan="1" rowspan="1">A crucial therapeutic target in various solid tumors</td>
<td align="left" colspan="1" rowspan="1">Enhanced T cell infiltration by designing EGFR CAR-T cells with CXCR5</td>
<td align="left" colspan="1" rowspan="1">Need for further research to improve CAR-T cell infiltration and persistence in solid tumors</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CLDN18.2</td>
<td align="left" colspan="1" rowspan="1">A promising target for anti-tumor therapy in multiple cancers</td>
<td align="left" colspan="1" rowspan="1">CT041, the first-in-class CAR-T product targeting CLDN18.2, shows disease control rate and objective response rate in clinical trials</td>
<td align="left" colspan="1" rowspan="1">Limited clinical data, need for further studies to confirm long-term effects and safety</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p35"><p>Note: CRS = Cytokine Release Syndrome</p></div></div></section><section class="tw xbox font-sm" id="Tab3"><h5 class="obj_head">Table 3.</h5>
<div class="caption p"><p>Consolidated table of clinical trials in CAR-T therapy for solid tumors</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Target Antigen</th>
<th align="left" colspan="1" rowspan="1">Trial Identifier</th>
<th align="left" colspan="1" rowspan="1">Phase</th>
<th align="left" colspan="1" rowspan="1">Indication</th>
<th align="left" colspan="1" rowspan="1">Cell Design</th>
<th align="left" colspan="1" rowspan="1">Response Rate</th>
<th align="left" colspan="1" rowspan="1">CRS/ICANS Incidence</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">MSLN</td>
<td align="left" colspan="1" rowspan="1">CT041</td>
<td align="left" colspan="1" rowspan="1">I/II</td>
<td align="left" colspan="1" rowspan="1">Pancreatic Cancer</td>
<td align="left" colspan="1" rowspan="1">Second-generation CAR-T</td>
<td align="left" colspan="1" rowspan="1">
<p>ORR: 54.9% (28/51)</p>
<p>DCR: 96.1% (49/51)</p>
</td>
<td align="left" colspan="1" rowspan="1">Not reported</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GPC3</td>
<td align="left" colspan="1" rowspan="1">C-CAR031</td>
<td align="left" colspan="1" rowspan="1">I</td>
<td align="left" colspan="1" rowspan="1">Hepatocellular Carcinoma</td>
<td align="left" colspan="1" rowspan="1">GPC3-specific CAR-T</td>
<td align="left" colspan="1" rowspan="1">
<p>ORR: 50.0% (11/22)</p>
<p>DCR: 90.9% (20/22)</p>
</td>
<td align="left" colspan="1" rowspan="1">Low-grade CRS in 22 patients</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GD2</td>
<td align="left" colspan="1" rowspan="1">GD2-CART01</td>
<td align="left" colspan="1" rowspan="1">I/II</td>
<td align="left" colspan="1" rowspan="1">Neuroblastoma</td>
<td align="left" colspan="1" rowspan="1">Third-generation CAR-T</td>
<td align="left" colspan="1" rowspan="1">ORR: 63% (17/27) CR: 33% (9/27)</td>
<td align="left" colspan="1" rowspan="1">Not reported</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">HER2</td>
<td align="left" colspan="1" rowspan="1">N/A</td>
<td align="left" colspan="1" rowspan="1">I</td>
<td align="left" colspan="1" rowspan="1">Advanced Sarcoma</td>
<td align="left" colspan="1" rowspan="1">HER2-specific CAR-T</td>
<td align="left" colspan="1" rowspan="1">
<p>ORR: 50% (7/14)</p>
<p>CR: 1 (1/14)</p>
</td>
<td align="left" colspan="1" rowspan="1">Grade 1–2 CRS in 9 patients</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CEA</td>
<td align="left" colspan="1" rowspan="1">N/A</td>
<td align="left" colspan="1" rowspan="1">I</td>
<td align="left" colspan="1" rowspan="1">Colorectal Cancer</td>
<td align="left" colspan="1" rowspan="1">CEA-specific CAR-T</td>
<td align="left" colspan="1" rowspan="1">
<p>ORR: 30% (3/10)</p>
<p>DCR: 70% (7/10)</p>
</td>
<td align="left" colspan="1" rowspan="1">Not reported</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">DLL3</td>
<td align="left" colspan="1" rowspan="1">AMG 119</td>
<td align="left" colspan="1" rowspan="1">I</td>
<td align="left" colspan="1" rowspan="1">Small Cell Lung Cancer</td>
<td align="left" colspan="1" rowspan="1">DLL3-specific CAR-T</td>
<td align="left" colspan="1" rowspan="1">
<p>ORR: 40% (4/10)</p>
<p>DCR: 80% (8/10)</p>
</td>
<td align="left" colspan="1" rowspan="1">Not reported</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GUCY2C</td>
<td align="left" colspan="1" rowspan="1">IM96</td>
<td align="left" colspan="1" rowspan="1">I</td>
<td align="left" colspan="1" rowspan="1">Metastatic Colorectal Cancer</td>
<td align="left" colspan="1" rowspan="1">GUCY2C-specific CAR-T</td>
<td align="left" colspan="1" rowspan="1">
<p>ORR: 26.3% (5/19)</p>
<p>DCR: 73.7% (14/19)</p>
</td>
<td align="left" colspan="1" rowspan="1">Not reported</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">EGFR</td>
<td align="left" colspan="1" rowspan="1">N/A</td>
<td align="left" colspan="1" rowspan="1">I</td>
<td align="left" colspan="1" rowspan="1">Non-Small Cell Lung Cancer</td>
<td align="left" colspan="1" rowspan="1">EGFR-specific CAR-T</td>
<td align="left" colspan="1" rowspan="1">
<p>ORR: 30% (3/10)</p>
<p>DCR: 70% (7/10)</p>
</td>
<td align="left" colspan="1" rowspan="1">Not reported</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CLDN18.2</td>
<td align="left" colspan="1" rowspan="1">CT041</td>
<td align="left" colspan="1" rowspan="1">I/II</td>
<td align="left" colspan="1" rowspan="1">Gastric Cancer</td>
<td align="left" colspan="1" rowspan="1">Second-generation CAR-T</td>
<td align="left" colspan="1" rowspan="1">
<p>ORR: 54.9% (28/51)</p>
<p>DCR: 96.1% (49/51)</p>
</td>
<td align="left" colspan="1" rowspan="1">Not reported</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p54"><p>Note: ORR = Overall Response Rate, DCR = Disease Control Rate, CRS = Cytokine Release Syndrome, ICANS = Immune Effector Cell-Associated Neurotoxicity Syndrome</p></div></div></section></section></section><section id="Sec18"><h3 class="pmc_sec_title">Difficulties in CAR-T treatment of solid tumors</h3>
<p id="Par28">Unlike treatments for hematological malignancies, CAR-T therapy still faces many new problems in the field of solid tumor treatment, including the heterogeneity of tumor antigens, insufficient CAR-T cell infiltration, poor proliferation and persistence, toxicity control, and immunosuppressive microenvironment (Fig. <a href="#Fig7" class="usa-link">7</a>).</p>
<figure class="fig xbox font-sm" id="Fig7"><h4 class="obj_head">Fig. 7.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374352_12935_2025_3938_Fig7_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f185/12374352/0bb64e5a427b/12935_2025_3938_Fig7_HTML.jpg" loading="lazy" id="d33e1523" height="456" width="669" alt="Fig. 7"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig7/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Challenges for CAR T-cell Immunotherapy in Solid Tumors. <strong>(A)</strong> The expression of tumor antigens shows significant heterogeneity between different patients or different cell populations. <strong>(B)</strong> Physical barriers obstruct CAR-T cell infiltration. <strong>(C)</strong> The distinctive immunosuppressive components of the tumor microenvironment diminish the efficacy of CAR-T cells. <strong>(D)</strong> Cytokine release syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome are the main adverse reactions of CAR-T therapy</p></figcaption></figure></section><section id="Sec19"><h3 class="pmc_sec_title">Target antigen selection</h3>
<p id="Par30">Despite the rapid progress in detection technology, the identification of effective target antigens remains a gradual process thus far. The heterogeneity of tumor antigens is a key reason. The expression of tumor antigens is significantly different in different patients with the same type of tumor and different cell populations of the same tumor, which makes the screening of antigens difficult. Besides, one of the major challenges in ensuring target safety is to avoid the “on-target off-tumor” effect: non-specific expression of the target antigen on healthy cells can stimulate CAR-T cells, resulting in damage to normal tissues and posing a potential life-threatening risk to patients. The primary mechanism through which CAR-T cells induce damage to normal cells involves the release of perforin and granzymes. This process is coupled with the upregulation of T cell surface molecules, leading to target cell apoptosis or the secretion of cytokines. Therefore, in the pursuit of creating CAR-T cells that are both safe and efficacious for patients with solid tumors, the identification of new antigens is crucial. These antigens should be selectively expressed exclusively on malignant cells and absent in non-malignant cells. Measures currently available to address this problem include fine-tuning CAR domains, constructing Logic-gated CAR-T cells, control via suicide switches or by regulating cytotoxicity and CAR expression and local injection [<a href="#CR98" class="usa-link" aria-describedby="CR98">98</a>].</p></section><section id="Sec20"><h3 class="pmc_sec_title">Physical barriers</h3>
<p id="Par31">CAR-T may encounter barriers while entering some solid tumors, such as the blood-brain barrier (BBB) in treating CNS tumors. Traditional intravenous administration makes it difficult for CAR-T cells to pass through BBB. Hence, laser thermotherapy, electroporation, transcranial ultrasound and many other techniques have been explored to modify the BBB, which has been proposed as a potential avenue for the delivery of CAR T-cell therapy. Additionally, alternative methods such as direct delivery to the brain or the intraventricular system are being investigated to provide a targeted approach to therapy [<a href="#CR99" class="usa-link" aria-describedby="CR99">99</a>, <a href="#CR100" class="usa-link" aria-describedby="CR100">100</a>]. It has been proved that intraventricular therapy delivery has the advantage of bypassing many obstacles within the brain parenchyma [<a href="#CR101" class="usa-link" aria-describedby="CR101">101</a>]. However, researchers found that BBB disruption can trigger CNS-related side-effects including brain swelling [<a href="#CR102" class="usa-link" aria-describedby="CR102">102</a>]. In addition to physiological barriers, the solid tumor itself also has a physical barrier. Activated cancer-associated fibroblasts contribute to the formation of thicker and mechanically stressed collagen fibers, providing structural support for tumor growth. Simultaneously, in solid tumors, the basement membranes often experience breaches facilitated by both proteolytic degradation and force-induced realignment of molecular components within the ECM [<a href="#CR103" class="usa-link" aria-describedby="CR103">103</a>], thus obstructing CAR-T cell infiltration.</p></section><section id="Sec21"><h3 class="pmc_sec_title">Antigen escape</h3>
<p id="Par32">Solid tumors exhibit significant antigen heterogeneity, and clinical studies have indicated a swift occurrence of antigen escape from therapy. This rapid escape curtails the persistence and effectiveness of CAR-T cells [<a href="#CR87" class="usa-link" aria-describedby="CR87">87</a>]. It can happen either through mutation of cancer cells or by proliferating from a cell without the antigen that existed from the time of treatment [<a href="#CR104" class="usa-link" aria-describedby="CR104">104</a>]. Therefore, CAR-T cells that target multiple antigens is an available method to refine on this challenge. CAR-T cells targeting two single antigens, in a double-antigen-targeted approach, effectively overcome the challenge of antigen escape and enhance the specificity for target antigens [<a href="#CR105" class="usa-link" aria-describedby="CR105">105</a>]. Common modes of dual-target CAR-T include combination of two CAR-T cells, bicistronic CAR-T cells and tandem bispecific CAR-T cells [<a href="#CR106" class="usa-link" aria-describedby="CR106">106</a>].</p></section><section id="Sec22"><h3 class="pmc_sec_title">Immunosuppressive microenvironment</h3>
<p id="Par33">In solid tumors, the distinctive immunosuppressive components of the tumor microenvironment (TME) play a role in the diminished efficacy of CAR-T cells. Previous studies have shown that merely 1–2% of CAR-T cells can finally infiltrate the core of the tumor, leading to a substantial reduction in killing efficiency [<a href="#CR107" class="usa-link" aria-describedby="CR107">107</a>].The heterogenous constituents of the TME include a diverse array of cells such as natural killer cells, tumor-associated macrophages [<a href="#CR108" class="usa-link" aria-describedby="CR108">108</a>], myeloid-derived suppressor cells, myeloid progenitor cells, effector and regulatory T cells, and dendritic cells, matrix proteins including an extracellular matrix comprised of proteoglycans, fibrous proteins, stromal cells, glycoproteins, and polysaccharides, and secreted factors like chemokines, cytokines, and other proteins [<a href="#CR109" class="usa-link" aria-describedby="CR109">109</a>], which can block CAR-T cells by means of forming immunosuppressive cell barrier, affecting the intricate interplay of signaling or altering immune cell direction. Moreover, the insufficient levels of nutrients and oxygen, coupled with the accumulation of metabolic waste, contribute significantly to the highly immunosuppressive nature of the tumor microenvironment [<a href="#CR110" class="usa-link" aria-describedby="CR110">110</a>]. Additionally, the presence of abnormal vascular beds and elevated interstitial fibrosis in solid tumors hampers the effective delivery of CAR-T cells or drugs to the deeper regions of the tumor [<a href="#CR111" class="usa-link" aria-describedby="CR111">111</a>]. Co-Treatment with immune checkpoint inhibitors might be an outstanding means to overcome this challenge [<a href="#CR112" class="usa-link" aria-describedby="CR112">112</a>].</p></section><section id="Sec23"><h3 class="pmc_sec_title">Adverse reactions</h3>
<p id="Par34">CAR-T cell therapy may cause serious adverse reactions, mainly cytokine release syndrome (CRS) and neurotoxicity, which can occur during the treatment of either solid or non-solid tumors (Fig. <a href="#Fig8" class="usa-link">8</a>A). CRS stems from the excessive production of inflammatory cytokines induced by supraphysiological levels of immune activation. This can manifest as a clinical constellation of severe symptoms, such as fatigue, nausea, fever, muscle pain, low blood pressure, general discomfort, reduced oxygen levels, blood clotting disorders, capillary leakage, or multiorgan dysfunction, and may pose a risk of lethality [<a href="#CR113" class="usa-link" aria-describedby="CR113">113</a>]. Drugs like tocilizumab alone or with steroids are applied to severe CRS [<a href="#CR114" class="usa-link" aria-describedby="CR114">114</a>]. Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) is a neurotoxicity related to CAR-T cell therapy that has the potential to be life-threatening [<a href="#CR115" class="usa-link" aria-describedby="CR115">115</a>], which can trigger symptoms like delirium, aphasia, encephalopathy, seizures and tremor, and in rare cases, rapid-onset cerebral edema [<a href="#CR116" class="usa-link" aria-describedby="CR116">116</a>]. Possible pathogenesis includes BBB disruption and specific production of IL6, IL8, IP10, and MCP1 [<a href="#CR117" class="usa-link" aria-describedby="CR117">117</a>]. When constructing new generations of CAR, the mere incorporation of a co-stimulation domain may lead to the emergence of severe side effects. To mitigate these complications, pro-apoptotic suicide gene including iCaspase9, has recently been integrated in some researches so that cytotoxic injuries and systemic effects can be terminated in time (Fig. <a href="#Fig8" class="usa-link">8</a>B) [<a href="#CR118" class="usa-link" aria-describedby="CR118">118</a>].</p>
<figure class="fig xbox font-sm" id="Fig8"><h4 class="obj_head">Fig. 8.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374352_12935_2025_3938_Fig8_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f185/12374352/32c41f3eb107/12935_2025_3938_Fig8_HTML.jpg" loading="lazy" id="d33e1644" height="279" width="669" alt="Fig. 8"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig8/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Adverse reactions and solutions. <strong>(A)</strong> Risk factors for CRS and neurotoxicity [<a href="#CR113" class="usa-link" aria-describedby="CR113">113</a>]. Copyright 2018 All the authors. Licensee <a href="http://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by/4.0/</a>. <strong>(B)</strong> A few types of “off switches” or suicide genes can be manipulated to alter the behavior of CAR-T cells by controlling whether CAR-T cell receptors are degraded or are able to be expressed [<a href="#CR115" class="usa-link" aria-describedby="CR115">115</a>]. Copyright 2022 Sterner and Sterner. Licensee CC BY 4.0. All these figures are not modified</p></figcaption></figure></section></section><section id="Sec24"><h2 class="pmc_sec_title">Discussion</h2>
<p id="Par36">If CAR-T cells continue to face challenges in treating solid tumors, several alternative novel immunotherapeutic strategies could be considered. These include bispecific antibodies (BsAbs) that redirect T cells to tumor cells, antibody-drug conjugates (ADCs) that deliver cytotoxic drugs directly to cancer cells, oncolytic viruses that selectively infect and lyse tumor cells, immune checkpoint inhibitors that block inhibitory signals and enhance T cell activity, cancer vaccines that stimulate the immune system to recognize and attack cancer cells, natural killer (NK) cells that can be engineered to target tumors, macrophage-targeted therapies that reprogram tumor-associated macrophages, and combination therapies that integrate multiple strategies to address various aspects of tumor immunology. More detailed research on these and other immunotherapeutic approaches can be found in other immunology articles and will not be reiterated here. Each of these approaches has shown promise in preclinical and early clinical studies, and their continued development could lead to significant advancements in the treatment of solid tumors.</p></section><section id="Sec25"><h2 class="pmc_sec_title">Summary</h2>
<p id="Par37">CAR-T cell therapy in solid tumors is gradually maturing, and related technologies are flourishing. For the moment, the tumor microenvironment and the intrinsic factors of T cells are the main reasons for the poor efficacy of CAR-T cells. Researchers have used genetic engineering techniques to modify CAR-T cells to break through these barriers and increase the function of CAR-T cells. At present, CAR has been built to the fifth generation, and it is certain that there will be a newer generation of CAR in the future to address the shortcomings of CAR-T therapy in clinic from the structure of the cell itself, including designing updated scFv fragments, adding new fragments in the intracellular domain, knocking out or modulating immunosuppressive targets, etc. to achieve the goal of controlling adverse reactions such as cytotoxicity, enhancing cell proliferation ability, strengthening cell targeting ability and overcoming immunosuppressive environment. Furthermore, the potent combination with IL-2 receptors, co-stimulatory molecules, TCR signaling complexes, and chemokine receptors to enhance CAR-T receptor signaling and improve CAR-T cell migration into hostile tumor microenvironments is also a direction worth considering for next generation of CAR.</p>
<p id="Par38">In addition, new therapeutic modalities such as nanocarriers [<a href="#CR119" class="usa-link" aria-describedby="CR119">119</a>], cancer vaccines [<a href="#CR120" class="usa-link" aria-describedby="CR120">120</a>], dual targets and cytokine combination therapy have also greatly enhanced the efficacy of CAR-T, and achieved remarkable results in clinical trials. It is foreseeable that newer CAR-T treatment models will be emerge in the future, and the existing technology will be combined with CAR-T to play a better role.</p>
<p id="Par39">As a burgeoning cancer treatment, CAR-T cell therapy in solid tumors has a prosperous future. At present, CAR-T therapy has already achieved some success in the treatment of solid tumors. Although it still faces some challenges, such as high treatment cost and some side effects, it is believed that with the continuous innovation and improvement of technology, CAR-T will have broad potential for development in the field of solid tumor treatment because of its outstanding clinical efficacy and technology specificity and will also make greater contributions to the anti-tumor cause.</p></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>Not applicable.</p></section><section id="notes1"><h2 class="pmc_sec_title">Author contributions</h2>
<p>Jiajun Zhu: Writing– original draft, Writing– review &amp; editing, Validation, Project administration, Conceptualization. Jianming Zhou: Writing– review &amp; editing, Validation, Software, Investigation. Yiting Tang: Writing– review &amp; editing, Validation, Software, Investigation. Ruotong Huang: Writing– review &amp; editing, Validation, Software. Chengjia Lu: Writing– review &amp; editing, Validation, Software. Ke Qian: Writing– review &amp; editing, Validation, Software. Qingyu Zhou: Validation, Software, Investigation. Jingjun Zhang: Validation, Software, Investigation. Xiaoyi Yang: Writing– review &amp; editing, Validation, Software. Wenhan Zhou: Writing– review &amp; editing, Validation, Software. Jiaqiang Wu: Validation, Software, Investigation. Qiudan Chen: Writing– review &amp; editing, Validation, Software, Investigation. Yong Lin: Validation, Software, Investigation. Shuying Chen: Writing– review &amp; editing, Validation, Supervision, Software, Resources, Project administration, Methodology, Investigation, Funding acquisition, Conceptualization.</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>This research was funded by Shanghai Pujiang Talent Program (24PJA012; S.C.), National Natural Science Foundation of China (82102491; S.C.), National Key Research and Development Plan of China (2018YFC2000200; Y.L.), Shanghai Municipal Science and Technology Commission (GWVI-11.1-27; Y.L.) and Clinical Research Project of Shanghai Municipal Health Commission (202140240; Q.C.).</p></section><section id="notes3"><h2 class="pmc_sec_title">Data availability</h2>
<p>No datasets were generated or analysed during the current study.</p></section><section id="notes4"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar4"><h3 class="pmc_sec_title">Ethics approval and consent to participate</h3>
<p id="Par40">Not applicable.</p></section><section id="FPar5"><h3 class="pmc_sec_title">Consent for publication</h3>
<p id="Par41">Not applicable.</p></section><section id="FPar6"><h3 class="pmc_sec_title">Competing interests</h3>
<p id="Par42">The authors declare no competing interests.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1">
<p><strong>Publisher’s note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div></div></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Qiudan Chen, Email: chen_qiudan@163.com.</p>
<p>Yong Lin, Email: yonglin700704@gmail.com.</p>
<p>Shuying Chen, Email: shuyingchen@fudan.edu.cn.</p></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra138.</cite> [<a href="https://doi.org/10.1126/scitranslmed.3005930" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3742551/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23515080/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Brentjens%20RJ,%20Davila%20ML,%20Riviere%20I,%20Park%20J,%20Wang%20X,%20Cowell%20LG,%20Bartido%20S,%20Stefanski%20J,%20Taylor%20C,%20Olszewska%20M,%20et%20al.%20CD19-targeted%20T%20cells%20rapidly%20induce%20molecular%20remissions%20in%20adults%20with%20chemotherapy-refractory%20acute%20lymphoblastic%20leukemia.%20Sci%20Transl%20Med.%202013;5(177):177ra138." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Geoffrion D, Whittaker H. Tisagenlecleucel in diffuse large B-Cell lymphoma. N Engl J Med. 2019;380(16):1585.
</cite> [<a href="https://doi.org/10.1056/NEJMc1901464" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30995382/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Geoffrion%20D,%20Whittaker%20H.%20Tisagenlecleucel%20in%20diffuse%20large%20B-Cell%20lymphoma.%20N%20Engl%20J%20Med.%202019;380(16):1585." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S, Nagase F, Kurosawa Y. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun. 1987;149(3):960–8.
</cite> [<a href="https://doi.org/10.1016/0006-291x(87)90502-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/3122749/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kuwana%20Y,%20Asakura%20Y,%20Utsunomiya%20N,%20Nakanishi%20M,%20Arata%20Y,%20Itoh%20S,%20Nagase%20F,%20Kurosawa%20Y.%20Expression%20of%20chimeric%20receptor%20composed%20of%20immunoglobulin-derived%20V%20regions%20and%20T-cell%20receptor-derived%20C%20regions.%20Biochem%20Biophys%20Res%20Commun.%201987;149(3):960%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the Immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA. 1993;90(2):720–4.
</cite> [<a href="https://doi.org/10.1073/pnas.90.2.720" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC45737/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8421711/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Eshhar%20Z,%20Waks%20T,%20Gross%20G,%20Schindler%20DG.%20Specific%20activation%20and%20targeting%20of%20cytotoxic%20lymphocytes%20through%20chimeric%20single%20chains%20consisting%20of%20antibody-binding%20domains%20and%20the%20gamma%20or%20zeta%20subunits%20of%20the%20Immunoglobulin%20and%20T-cell%20receptors.%20Proc%20Natl%20Acad%20Sci%20USA.%201993;90(2):720%E2%80%934." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Finney HM, Lawson AD, Bebbington CR, Weir AN. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol (Baltimore Md: 1950). 1998;161(6):2791–7.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/9743337/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Finney%20HM,%20Lawson%20AD,%20Bebbington%20CR,%20Weir%20AN.%20Chimeric%20receptors%20providing%20both%20primary%20and%20costimulatory%20signaling%20in%20T%20cells%20from%20a%20single%20gene%20product.%20J%20Immunol%20(Baltimore%20Md:%201950).%201998;161(6):2791%E2%80%937." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol (Baltimore Md: 1950). 2004;172(1):104–13.</cite> [<a href="https://doi.org/10.4049/jimmunol.172.1.104" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14688315/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Finney%20HM,%20Akbar%20AN,%20Lawson%20AD.%20Activation%20of%20resting%20human%20primary%20T%20cells%20with%20chimeric%20receptors:%20costimulation%20from%20CD28,%20inducible%20costimulator,%20CD134,%20and%20CD137%20in%20series%20with%20signals%20from%20the%20TCR%20zeta%20chain.%20J%20Immunol%20(Baltimore%20Md:%201950).%202004;172(1):104%E2%80%9313." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Pulè MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Therapy: J Am Soc Gene Therapy. 2005;12(5):933–41.</cite> [<a href="https://doi.org/10.1016/j.ymthe.2005.04.016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15979412/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Pul%C3%A8%20MA,%20Straathof%20KC,%20Dotti%20G,%20Heslop%20HE,%20Rooney%20CM,%20Brenner%20MK.%20A%20chimeric%20T%20cell%20antigen%20receptor%20that%20augments%20cytokine%20release%20and%20supports%20clonal%20expansion%20of%20primary%20human%20T%20cells.%20Mol%20Therapy:%20J%20Am%20Soc%20Gene%20Therapy.%202005;12(5):933%E2%80%9341." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Chmielewski M, Abken H. CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer. Cancer Immunol Immunotherapy: CII. 2012;61(8):1269–77.
</cite> [<a href="https://doi.org/10.1007/s00262-012-1202-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11029721/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22274776/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chmielewski%20M,%20Abken%20H.%20CAR%20T%20cells%20transform%20to%20trucks:%20chimeric%20antigen%20receptor-redirected%20T%20cells%20engineered%20to%20deliver%20inducible%20IL-12%20modulate%20the%20tumour%20stroma%20to%20combat%20cancer.%20Cancer%20Immunol%20Immunotherapy:%20CII.%202012;61(8):1269%E2%80%9377." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Tokarew N, Ogonek J, Endres S, von Bergwelt-Baildon M, Kobold S. Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer. 2019;120(1):26–37.
</cite> [<a href="https://doi.org/10.1038/s41416-018-0325-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6325111/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30413825/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tokarew%20N,%20Ogonek%20J,%20Endres%20S,%20von%20Bergwelt-Baildon%20M,%20Kobold%20S.%20Teaching%20an%20old%20dog%20new%20tricks:%20next-generation%20CAR%20T%20cells.%20Br%20J%20Cancer.%202019;120(1):26%E2%80%9337." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang CH, Saso K, Butler MO, Minden MD, Hirano N. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat Med. 2018;24(3):352–9.
</cite> [<a href="https://doi.org/10.1038/nm.4478" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5839992/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29400710/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kagoya%20Y,%20Tanaka%20S,%20Guo%20T,%20Anczurowski%20M,%20Wang%20CH,%20Saso%20K,%20Butler%20MO,%20Minden%20MD,%20Hirano%20N.%20A%20novel%20chimeric%20antigen%20receptor%20containing%20a%20JAK-STAT%20signaling%20domain%20mediates%20superior%20antitumor%20effects.%20Nat%20Med.%202018;24(3):352%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>ji C, You F, Zhang T, Fan S, Han Z, Xiang S, Wang Y, Sheng B, Wang T, An G, et al. Novel anti-GD2 CAR-T cells exhibit superior cytotoxicity against neuroblastoma. Eur J Inflamm. 2020;18:205873922096119.</cite> [<a href="https://scholar.google.com/scholar_lookup?ji%20C,%20You%20F,%20Zhang%20T,%20Fan%20S,%20Han%20Z,%20Xiang%20S,%20Wang%20Y,%20Sheng%20B,%20Wang%20T,%20An%20G,%20et%20al.%20Novel%20anti-GD2%20CAR-T%20cells%20exhibit%20superior%20cytotoxicity%20against%20neuroblastoma.%20Eur%20J%20Inflamm.%202020;18:205873922096119." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Ali S, Toews K, Schwiebert S, Klaus A, Winkler A, Grunewald L, Oevermann L, Deubzer HE, Tüns A, Jensen MC, et al. Tumor-Derived extracellular vesicles impair CD171-Specific CD4(+) CAR T cell efficacy. Front Immunol. 2020;11:531.
</cite> [<a href="https://doi.org/10.3389/fimmu.2020.00531" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7137471/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32296437/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ali%20S,%20Toews%20K,%20Schwiebert%20S,%20Klaus%20A,%20Winkler%20A,%20Grunewald%20L,%20Oevermann%20L,%20Deubzer%20HE,%20T%C3%BCns%20A,%20Jensen%20MC,%20et%20al.%20Tumor-Derived%20extracellular%20vesicles%20impair%20CD171-Specific%20CD4(+)%20CAR%20T%20cell%20efficacy.%20Front%20Immunol.%202020;11:531." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Yarmarkovich M, Marshall QF, Warrington JM, Premaratne R, Farrel A, Groff D, Li W, di Marco M, Runbeck E, Truong H, et al. Targeting of intracellular oncoproteins with peptide-centric cars. Nature. 2023;623(7988):820–7.
</cite> [<a href="https://doi.org/10.1038/s41586-023-06706-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10665195/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37938771/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yarmarkovich%20M,%20Marshall%20QF,%20Warrington%20JM,%20Premaratne%20R,%20Farrel%20A,%20Groff%20D,%20Li%20W,%20di%20Marco%20M,%20Runbeck%20E,%20Truong%20H,%20et%20al.%20Targeting%20of%20intracellular%20oncoproteins%20with%20peptide-centric%20cars.%20Nature.%202023;623(7988):820%E2%80%937." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Cui J, Zhang Q, Song Q, Wang H, Dmitriev P, Sun MY, Cao X, Wang Y, Guo L, Indig IH, et al. Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastoma. Neurooncology. 2019;21(11):1436–46.</cite> [<a href="https://doi.org/10.1093/neuonc/noz117" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6827823/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31276594/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cui%20J,%20Zhang%20Q,%20Song%20Q,%20Wang%20H,%20Dmitriev%20P,%20Sun%20MY,%20Cao%20X,%20Wang%20Y,%20Guo%20L,%20Indig%20IH,%20et%20al.%20Targeting%20hypoxia%20downstream%20signaling%20protein,%20CAIX,%20for%20CAR%20T-cell%20therapy%20against%20glioblastoma.%20Neurooncology.%202019;21(11):1436%E2%80%9346." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Durgin JS, Henderson F Jr., Nasrallah MP, Mohan S, Wang S, Lacey SF, Melenhorst JJ, Desai AS, Lee JYK, Maus MV, et al. Case report: prolonged survival following EGFRvIII CAR T cell treatment for recurrent glioblastoma. Front Oncol. 2021;11:669071.
</cite> [<a href="https://doi.org/10.3389/fonc.2021.669071" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8138201/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34026647/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Durgin%20JS,%20Henderson%20F%20Jr.,%20Nasrallah%20MP,%20Mohan%20S,%20Wang%20S,%20Lacey%20SF,%20Melenhorst%20JJ,%20Desai%20AS,%20Lee%20JYK,%20Maus%20MV,%20et%20al.%20Case%20report:%20prolonged%20survival%20following%20EGFRvIII%20CAR%20T%20cell%20treatment%20for%20recurrent%20glioblastoma.%20Front%20Oncol.%202021;11:669071." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Wang SS, Davenport AJ, Iliopoulos M, Hughes-Parry HE, Watson KA, Arcucci V, Mulazzani M, Eisenstat DD, Hansford JR, Cross RS, et al. HER2 chimeric antigen receptor T cell immunotherapy is an effective treatment for diffuse intrinsic Pontine glioma. Neuro-oncology Adv. 2023;5(1):vdad024.</cite> [<a href="https://doi.org/10.1093/noajnl/vdad024" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10158089/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37152812/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20SS,%20Davenport%20AJ,%20Iliopoulos%20M,%20Hughes-Parry%20HE,%20Watson%20KA,%20Arcucci%20V,%20Mulazzani%20M,%20Eisenstat%20DD,%20Hansford%20JR,%20Cross%20RS,%20et%20al.%20HER2%20chimeric%20antigen%20receptor%20T%20cell%20immunotherapy%20is%20an%20effective%20treatment%20for%20diffuse%20intrinsic%20Pontine%20glioma.%20Neuro-oncology%20Adv.%202023;5(1):vdad024." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Holzinger A, Abken H. CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target. Cancer Immunol Immunotherapy: CII. 2017;66(11):1505–7.
</cite> [<a href="https://doi.org/10.1007/s00262-017-2045-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11029415/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28755091/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Holzinger%20A,%20Abken%20H.%20CAR%20T%20cells%20targeting%20solid%20tumors:%20carcinoembryonic%20antigen%20(CEA)%20proves%20to%20be%20a%20safe%20target.%20Cancer%20Immunol%20Immunotherapy:%20CII.%202017;66(11):1505%E2%80%937." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>da Cunha Santos G, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Annu Rev Pathol. 2011;6:49–69.
</cite> [<a href="https://doi.org/10.1146/annurev-pathol-011110-130206" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20887192/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?da%20Cunha%20Santos%20G,%20Shepherd%20FA,%20Tsao%20MS.%20EGFR%20mutations%20and%20lung%20cancer.%20Annu%20Rev%20Pathol.%202011;6:49%E2%80%9369." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Mar N, Vredenburgh JJ, Wasser JS. Targeting HER2 in the treatment of non-small cell lung cancer. Lung Cancer (Amsterdam Netherlands). 2015;87(3):220–5.
</cite> [<a href="https://doi.org/10.1016/j.lungcan.2014.12.018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25601485/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mar%20N,%20Vredenburgh%20JJ,%20Wasser%20JS.%20Targeting%20HER2%20in%20the%20treatment%20of%20non-small%20cell%20lung%20cancer.%20Lung%20Cancer%20(Amsterdam%20Netherlands).%202015;87(3):220%E2%80%935." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Kachala SS, Bograd AJ, Villena-Vargas J, Suzuki K, Servais EL, Kadota K, Chou J, Sima CS, Vertes E, Rusch VW, et al. Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. Clin Cancer Research: Official J Am Association Cancer Res. 2014;20(4):1020–8.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-13-1862" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3944669/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24334761/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kachala%20SS,%20Bograd%20AJ,%20Villena-Vargas%20J,%20Suzuki%20K,%20Servais%20EL,%20Kadota%20K,%20Chou%20J,%20Sima%20CS,%20Vertes%20E,%20Rusch%20VW,%20et%20al.%20Mesothelin%20overexpression%20is%20a%20marker%20of%20tumor%20aggressiveness%20and%20is%20associated%20with%20reduced%20recurrence-free%20and%20overall%20survival%20in%20early-stage%20lung%20adenocarcinoma.%20Clin%20Cancer%20Research:%20Official%20J%20Am%20Association%20Cancer%20Res.%202014;20(4):1020%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Kim Y, Kim HS, Cui ZY, Lee HS, Ahn JS, Park CK, Park K, Ahn MJ. Clinicopathological implications of EpCAM expression in adenocarcinoma of the lung. Anticancer Res. 2009;29(5):1817–22.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/19443410/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kim%20Y,%20Kim%20HS,%20Cui%20ZY,%20Lee%20HS,%20Ahn%20JS,%20Park%20CK,%20Park%20K,%20Ahn%20MJ.%20Clinicopathological%20implications%20of%20EpCAM%20expression%20in%20adenocarcinoma%20of%20the%20lung.%20Anticancer%20Res.%202009;29(5):1817%E2%80%9322." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Tian W, Zhao J, Wang W. Targeting CDH17 with chimeric antigen Receptor-Redirected T cells in small cell lung cancer. Lung. 2023;201(5):489–97.
</cite> [<a href="https://doi.org/10.1007/s00408-023-00648-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37823901/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tian%20W,%20Zhao%20J,%20Wang%20W.%20Targeting%20CDH17%20with%20chimeric%20antigen%20Receptor-Redirected%20T%20cells%20in%20small%20cell%20lung%20cancer.%20Lung.%202023;201(5):489%E2%80%9397." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Gao H, Li K, Tu H, Pan X, Jiang H, Shi B, Kong J, Wang H, Yang S, Gu J, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Research: Official J Am Association Cancer Res. 2014;20(24):6418–28.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-14-1170" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25320357/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gao%20H,%20Li%20K,%20Tu%20H,%20Pan%20X,%20Jiang%20H,%20Shi%20B,%20Kong%20J,%20Wang%20H,%20Yang%20S,%20Gu%20J,%20et%20al.%20Development%20of%20T%20cells%20redirected%20to%20glypican-3%20for%20the%20treatment%20of%20hepatocellular%20carcinoma.%20Clin%20Cancer%20Research:%20Official%20J%20Am%20Association%20Cancer%20Res.%202014;20(24):6418%E2%80%9328." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Sun L, Gao F, Gao Z, Ao L, Li N, Ma S, Jia M, Li N, Lu P, Sun B et al. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in hepatocellular carcinoma. J Immunother Cancer 2021, 9(4).</cite> [<a href="https://doi.org/10.1136/jitc-2020-001875" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8039282/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33833049/" class="usa-link">PubMed</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Katz SC, Moody AE, Guha P, Hardaway JC, Prince E, LaPorte J, Stancu M, Slansky JE, Jordan KR, Schulick RD et al. HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery. <em>Journal for immunotherapy of cancer</em> 2020, 8(2).</cite> [<a href="https://doi.org/10.1136/jitc-2020-001097" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7449487/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32843493/" class="usa-link">PubMed</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Zhao Y, Zhu X, Shen J, Xu Y, zhi y, Qi Y, Chen J, Hong J, Wang L, Qin L, et al. Armed CEA CAR-T with a SIRPγ-CD28 chimeric co-receptor to exhibit the enhanced antitumor activity in preclinical study of colorectal cancer. J Clin Oncol. 2023;41:e14530–14530.</cite> [<a href="https://scholar.google.com/scholar_lookup?Zhao%20Y,%20Zhu%20X,%20Shen%20J,%20Xu%20Y,%20zhi%20y,%20Qi%20Y,%20Chen%20J,%20Hong%20J,%20Wang%20L,%20Qin%20L,%20et%20al.%20Armed%20CEA%20CAR-T%20with%20a%20SIRP%CE%B3-CD28%20chimeric%20co-receptor%20to%20exhibit%20the%20enhanced%20antitumor%20activity%20in%20preclinical%20study%20of%20colorectal%20cancer.%20J%20Clin%20Oncol.%202023;41:e14530%E2%80%9314530." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Feng Z, He X, Zhang X, Wu Y, Xing B, Knowles A, Shan Q, Miller S, Hojnacki T, Ma J, et al. Potent suppression of neuroendocrine tumors and Gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues. Nat Cancer. 2022;3(5):581–94.
</cite> [<a href="https://doi.org/10.1038/s43018-022-00344-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35314826/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Feng%20Z,%20He%20X,%20Zhang%20X,%20Wu%20Y,%20Xing%20B,%20Knowles%20A,%20Shan%20Q,%20Miller%20S,%20Hojnacki%20T,%20Ma%20J,%20et%20al.%20Potent%20suppression%20of%20neuroendocrine%20tumors%20and%20Gastrointestinal%20cancers%20by%20CDH17CAR%20T%20cells%20without%20toxicity%20to%20normal%20tissues.%20Nat%20Cancer.%202022;3(5):581%E2%80%9394." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>Magee MS, Abraham TS, Baybutt TR, Flickinger JC Jr., Ridge NA, Marszalowicz GP, Prajapati P, Hersperger AR, Waldman SA, Snook AE. Human GUCY2C-Targeted chimeric antigen receptor (CAR)-Expressing T cells eliminate colorectal cancer metastases. Cancer Immunol Res. 2018;6(5):509–16.
</cite> [<a href="https://doi.org/10.1158/2326-6066.CIR-16-0362" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5932207/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29615399/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Magee%20MS,%20Abraham%20TS,%20Baybutt%20TR,%20Flickinger%20JC%20Jr.,%20Ridge%20NA,%20Marszalowicz%20GP,%20Prajapati%20P,%20Hersperger%20AR,%20Waldman%20SA,%20Snook%20AE.%20Human%20GUCY2C-Targeted%20chimeric%20antigen%20receptor%20(CAR)-Expressing%20T%20cells%20eliminate%20colorectal%20cancer%20metastases.%20Cancer%20Immunol%20Res.%202018;6(5):509%E2%80%9316." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Garouniatis A, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Papavassiliou AG. FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk. <em>International journal of colorectal disease</em> 2013, 28(1):9–18.</cite> [<a href="https://doi.org/10.1007/s00384-012-1520-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22733437/" class="usa-link">PubMed</a>]</li>
<li id="CR30">
<span class="label">30.</span><cite>Deng X, Gao F, Li N, Li Q, Zhou Y, Yang T, Cai Z, Du P, Chen F, Cai J. Antitumor activity of NKG2D CAR-T cells against human colorectal cancer cells in vitro and in vivo. Am J Cancer Res. 2019;9(5):945–58.
</cite> [<a href="/articles/PMC6556598/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31218103/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Deng%20X,%20Gao%20F,%20Li%20N,%20Li%20Q,%20Zhou%20Y,%20Yang%20T,%20Cai%20Z,%20Du%20P,%20Chen%20F,%20Cai%20J.%20Antitumor%20activity%20of%20NKG2D%20CAR-T%20cells%20against%20human%20colorectal%20cancer%20cells%20in%20vitro%20and%20in%20vivo.%20Am%20J%20Cancer%20Res.%202019;9(5):945%E2%80%9358." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR31">
<span class="label">31.</span><cite>Chi X, Yang P, Zhang E, Gu J, Xu H, Li M, Gao X, Li X, Zhang Y, Xu H, et al. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with Recombinant human IL-12. Cancer Med. 2019;8(10):4753–65.
</cite> [<a href="https://doi.org/10.1002/cam4.2361" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6712469/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31237116/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chi%20X,%20Yang%20P,%20Zhang%20E,%20Gu%20J,%20Xu%20H,%20Li%20M,%20Gao%20X,%20Li%20X,%20Zhang%20Y,%20Xu%20H,%20et%20al.%20Significantly%20increased%20anti-tumor%20activity%20of%20carcinoembryonic%20antigen-specific%20chimeric%20antigen%20receptor%20T%20cells%20in%20combination%20with%20Recombinant%20human%20IL-12.%20Cancer%20Med.%202019;8(10):4753%E2%80%9365." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR32">
<span class="label">32.</span><cite>Han Y, Liu C, Li G, Li J, Lv X, Shi H, Liu J, Liu S, Yan P, Wang S, et al. Antitumor effects and persistence of a novel HER2 CAR T cells directed to gastric cancer in preclinical models. Am J Cancer Res. 2018;8(1):106–19.
</cite> [<a href="/articles/PMC5794725/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29416924/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Han%20Y,%20Liu%20C,%20Li%20G,%20Li%20J,%20Lv%20X,%20Shi%20H,%20Liu%20J,%20Liu%20S,%20Yan%20P,%20Wang%20S,%20et%20al.%20Antitumor%20effects%20and%20persistence%20of%20a%20novel%20HER2%20CAR%20T%20cells%20directed%20to%20gastric%20cancer%20in%20preclinical%20models.%20Am%20J%20Cancer%20Res.%202018;8(1):106%E2%80%9319." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR33">
<span class="label">33.</span><cite>Lv J, Zhao R, Wu D, Zheng D, Wu Z, Shi J, Wei X, Wu Q, Long Y, Lin S, et al. Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer. J Hematol Oncol. 2019;12(1):18.
</cite> [<a href="https://doi.org/10.1186/s13045-019-0704-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6380000/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30777106/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lv%20J,%20Zhao%20R,%20Wu%20D,%20Zheng%20D,%20Wu%20Z,%20Shi%20J,%20Wei%20X,%20Wu%20Q,%20Long%20Y,%20Lin%20S,%20et%20al.%20Mesothelin%20is%20a%20target%20of%20chimeric%20antigen%20receptor%20T%20cells%20for%20treating%20gastric%20cancer.%20J%20Hematol%20Oncol.%202019;12(1):18." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR34">
<span class="label">34.</span><cite>Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C, Vulto A, den Bakker M, Oosterwijk E, Debets R, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Therapy: J Am Soc Gene Therapy. 2013;21(4):904–12.</cite> [<a href="https://doi.org/10.1038/mt.2013.17" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5189272/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23423337/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lamers%20CH,%20Sleijfer%20S,%20van%20Steenbergen%20S,%20van%20Elzakker%20P,%20van%20Krimpen%20B,%20Groot%20C,%20Vulto%20A,%20den%20Bakker%20M,%20Oosterwijk%20E,%20Debets%20R,%20et%20al.%20Treatment%20of%20metastatic%20renal%20cell%20carcinoma%20with%20CAIX%20CAR-engineered%20T%20cells:%20clinical%20evaluation%20and%20management%20of%20on-target%20toxicity.%20Mol%20Therapy:%20J%20Am%20Soc%20Gene%20Therapy.%202013;21(4):904%E2%80%9312." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR35">
<span class="label">35.</span><cite>Li H, Ding J, Lu M, Liu H, Miao Y, Li L, Wang G, Zheng J, Pei D, Zhang Q. CAIX-specific CAR-T cells and Sunitinib show synergistic effects against metastatic renal cancer models. J Immunotherapy (Hagerstown Md: 1997). 2020;43(1):16–28.</cite> [<a href="https://doi.org/10.1097/CJI.0000000000000301" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31574023/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20H,%20Ding%20J,%20Lu%20M,%20Liu%20H,%20Miao%20Y,%20Li%20L,%20Wang%20G,%20Zheng%20J,%20Pei%20D,%20Zhang%20Q.%20CAIX-specific%20CAR-T%20cells%20and%20Sunitinib%20show%20synergistic%20effects%20against%20metastatic%20renal%20cancer%20models.%20J%20Immunotherapy%20(Hagerstown%20Md:%201997).%202020;43(1):16%E2%80%9328." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR36">
<span class="label">36.</span><cite>Yan W, Hu H, Tang B. Advances of chimeric antigen receptor T cell therapy in ovarian cancer. OncoTargets Therapy. 2019;12:8015–22.
</cite> [<a href="https://doi.org/10.2147/OTT.S203550" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6777428/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31686857/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yan%20W,%20Hu%20H,%20Tang%20B.%20Advances%20of%20chimeric%20antigen%20receptor%20T%20cell%20therapy%20in%20ovarian%20cancer.%20OncoTargets%20Therapy.%202019;12:8015%E2%80%9322." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR37">
<span class="label">37.</span><cite>Chen J, Hu J, Gu L, Ji F, Zhang F, Zhang M, Li J, Chen Z, Jiang L, Zhang Y, et al. Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer. Cancer Immunol Immunotherapy: CII. 2023;72(2):409–25.
</cite> [<a href="https://doi.org/10.1007/s00262-022-03238-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10991348/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35925286/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20J,%20Hu%20J,%20Gu%20L,%20Ji%20F,%20Zhang%20F,%20Zhang%20M,%20Li%20J,%20Chen%20Z,%20Jiang%20L,%20Zhang%20Y,%20et%20al.%20Anti-mesothelin%20CAR-T%20immunotherapy%20in%20patients%20with%20ovarian%20cancer.%20Cancer%20Immunol%20Immunotherapy:%20CII.%202023;72(2):409%E2%80%9325." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR38">
<span class="label">38.</span><cite>Che X, Yun U-J, Lee S, Kim Y, Lee J, Chae J, Suh J, Nam E-J, Kim GM, Kim H, et al. Abstract 1772: development of a novel L1CAM-targeted CAR-T, CX804, and its therapeutic efficacy in ovarian and gastric cancer. Cancer Res. 2023;83(7Supplement):1772–1772.</cite> [<a href="https://scholar.google.com/scholar_lookup?Che%20X,%20Yun%20U-J,%20Lee%20S,%20Kim%20Y,%20Lee%20J,%20Chae%20J,%20Suh%20J,%20Nam%20E-J,%20Kim%20GM,%20Kim%20H,%20et%20al.%20Abstract%201772:%20development%20of%20a%20novel%20L1CAM-targeted%20CAR-T,%20CX804,%20and%20its%20therapeutic%20efficacy%20in%20ovarian%20and%20gastric%20cancer.%20Cancer%20Res.%202023;83(7Supplement):1772%E2%80%931772." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR39">
<span class="label">39.</span><cite>Koneru M, O’Cearbhaill R, Pendharkar S, Spriggs DR, Brentjens RJ. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J Translational Med. 2015;13:102.</cite> [<a href="https://doi.org/10.1186/s12967-015-0460-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4438636/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25890361/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Koneru%20M,%20O%E2%80%99Cearbhaill%20R,%20Pendharkar%20S,%20Spriggs%20DR,%20Brentjens%20RJ.%20A%20phase%20I%20clinical%20trial%20of%20adoptive%20T%20cell%20therapy%20using%20IL-12%20secreting%20MUC-16(ecto)%20directed%20chimeric%20antigen%20receptors%20for%20recurrent%20ovarian%20cancer.%20J%20Translational%20Med.%202015;13:102." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR40">
<span class="label">40.</span><cite>Wang Y, Fang X, Li M, Ye J, Zhao S, Yu L, Wang J, Wang Y, Yan Z. Mesothelin CAR-T cells secreting PD-L1 blocking ScFv for pancreatic cancer treatment. Cancer Genet. 2022;268–269:103–10.
</cite> [<a href="https://doi.org/10.1016/j.cancergen.2022.10.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36288641/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20Y,%20Fang%20X,%20Li%20M,%20Ye%20J,%20Zhao%20S,%20Yu%20L,%20Wang%20J,%20Wang%20Y,%20Yan%20Z.%20Mesothelin%20CAR-T%20cells%20secreting%20PD-L1%20blocking%20ScFv%20for%20pancreatic%20cancer%20treatment.%20Cancer%20Genet.%202022;268%E2%80%93269:103%E2%80%9310." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR41">
<span class="label">41.</span><cite>Zhang E, Yang P, Gu J, Wu H, Chi X, Liu C, Wang Y, Xue J, Qi W, Sun Q, et al. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy. J Hematol Oncol. 2018;11(1):102.
</cite> [<a href="https://doi.org/10.1186/s13045-018-0646-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6090669/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30103775/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20E,%20Yang%20P,%20Gu%20J,%20Wu%20H,%20Chi%20X,%20Liu%20C,%20Wang%20Y,%20Xue%20J,%20Qi%20W,%20Sun%20Q,%20et%20al.%20Recombination%20of%20a%20dual-CAR-modified%20T%20lymphocyte%20to%20accurately%20eliminate%20pancreatic%20malignancy.%20J%20Hematol%20Oncol.%202018;11(1):102." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR42">
<span class="label">42.</span><cite>Yazdanifar M, Zhou R, Grover P, Williams C, Bose M, Moore LJ, Wu ST, Maher J, Dreau D, Mukherjee AP. Overcoming immunological resistance enhances the efficacy of A novel Anti-tMUC1-CAR T cell treatment against pancreatic ductal adenocarcinoma. Cells 2019, 8(9).</cite> [<a href="https://doi.org/10.3390/cells8091070" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6770201/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31514488/" class="usa-link">PubMed</a>]</li>
<li id="CR43">
<span class="label">43.</span><cite>Qi C, Xie T, Zhou J, Wang X, Gong J, Zhang X, Li J, Yuan J, Liu C, Shen L. CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer. J Hematol Oncol. 2023;16(1):102.
</cite> [<a href="https://doi.org/10.1186/s13045-023-01491-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10492318/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37689733/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Qi%20C,%20Xie%20T,%20Zhou%20J,%20Wang%20X,%20Gong%20J,%20Zhang%20X,%20Li%20J,%20Yuan%20J,%20Liu%20C,%20Shen%20L.%20CT041%20CAR%20T%20cell%20therapy%20for%20Claudin18.2-positive%20metastatic%20pancreatic%20cancer.%20J%20Hematol%20Oncol.%202023;16(1):102." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR44">
<span class="label">44.</span><cite>Weimin S, Abula A, Qianghong D, Wenguang W. Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression. Cancer Biol Ther. 2020;21(6):570–80.
</cite> [<a href="https://doi.org/10.1080/15384047.2020.1739952" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7515537/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32208880/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Weimin%20S,%20Abula%20A,%20Qianghong%20D,%20Wenguang%20W.%20Chimeric%20cytokine%20receptor%20enhancing%20PSMA-CAR-T%20cell-mediated%20prostate%20cancer%20regression.%20Cancer%20Biol%20Ther.%202020;21(6):570%E2%80%9380." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR45">
<span class="label">45.</span><cite>Dorff T, Blanchard S, Martirosyan H, Adkins L, Dhapola G, Moriarty A, Wagner J, Chaudhry A, D’Apuzzo M, Kuhn P, et al. Phase 1 study of PSCA-targeted chimeric antigen receptor (CAR) T cell therapy for metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2022;40:91–91.</cite> [<a href="https://scholar.google.com/scholar_lookup?Dorff%20T,%20Blanchard%20S,%20Martirosyan%20H,%20Adkins%20L,%20Dhapola%20G,%20Moriarty%20A,%20Wagner%20J,%20Chaudhry%20A,%20D%E2%80%99Apuzzo%20M,%20Kuhn%20P,%20et%20al.%20Phase%201%20study%20of%20PSCA-targeted%20chimeric%20antigen%20receptor%20(CAR)%20T%20cell%20therapy%20for%20metastatic%20castration-resistant%20prostate%20cancer%20(mCRPC).%20J%20Clin%20Oncol.%202022;40:91%E2%80%9391." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR46">
<span class="label">46.</span><cite>Yin L, Chen GL, Xiang Z, Liu YL, Li XY, Bi JW, Wang Q. Current progress in chimeric antigen receptor-modified T cells for the treatment of metastatic breast cancer. Biomed pharmacotherapy = Biomedecine Pharmacotherapie. 2023;162:114648.</cite> [<a href="https://doi.org/10.1016/j.biopha.2023.114648" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37023621/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yin%20L,%20Chen%20GL,%20Xiang%20Z,%20Liu%20YL,%20Li%20XY,%20Bi%20JW,%20Wang%20Q.%20Current%20progress%20in%20chimeric%20antigen%20receptor-modified%20T%20cells%20for%20the%20treatment%20of%20metastatic%20breast%20cancer.%20Biomed%20pharmacotherapy%20=%20Biomedecine%20Pharmacotherapie.%202023;162:114648." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR47">
<span class="label">47.</span><cite>Shah PD, Huang AC, Xu X, Orlowski R, Amaravadi RK, Schuchter LM, Zhang P, Tchou J, Matlawski T, Cervini A, et al. Phase I trial of autologous RNA-electroporated cMET-directed CAR T cells administered intravenously in patients with melanoma and breast carcinoma. Cancer Res Commun. 2023;3(5):821–9.
</cite> [<a href="https://doi.org/10.1158/2767-9764.CRC-22-0486" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10167933/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37377890/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shah%20PD,%20Huang%20AC,%20Xu%20X,%20Orlowski%20R,%20Amaravadi%20RK,%20Schuchter%20LM,%20Zhang%20P,%20Tchou%20J,%20Matlawski%20T,%20Cervini%20A,%20et%20al.%20Phase%20I%20trial%20of%20autologous%20RNA-electroporated%20cMET-directed%20CAR%20T%20cells%20administered%20intravenously%20in%20patients%20with%20melanoma%20and%20breast%20carcinoma.%20Cancer%20Res%20Commun.%202023;3(5):821%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR48">
<span class="label">48.</span><cite>Li H, Yuan W, Bin S, Wu G, Li P, Liu M, Yang J, Li X, Yang K, Gu H. Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 Blockade. Am J Cancer Res. 2020;10(2):688–703.
</cite> [<a href="/articles/PMC7061754/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32195036/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20H,%20Yuan%20W,%20Bin%20S,%20Wu%20G,%20Li%20P,%20Liu%20M,%20Yang%20J,%20Li%20X,%20Yang%20K,%20Gu%20H.%20Overcome%20trastuzumab%20resistance%20of%20breast%20cancer%20using%20anti-HER2%20chimeric%20antigen%20receptor%20T%20cells%20and%20PD1%20Blockade.%20Am%20J%20Cancer%20Res.%202020;10(2):688%E2%80%93703." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR49">
<span class="label">49.</span><cite>Zhang Q, Liu G, Liu J, Yang M, Fu J, Liu G, Li D, Gu Z, Zhang L, Pan Y, et al. The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice. Mol Therapy Oncolytics. 2021;20:556–68.</cite> [<a href="https://doi.org/10.1016/j.omto.2021.02.013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7943972/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33738341/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20Q,%20Liu%20G,%20Liu%20J,%20Yang%20M,%20Fu%20J,%20Liu%20G,%20Li%20D,%20Gu%20Z,%20Zhang%20L,%20Pan%20Y,%20et%20al.%20The%20antitumor%20capacity%20of%20mesothelin-CAR-T%20cells%20in%20targeting%20solid%20tumors%20in%20mice.%20Mol%20Therapy%20Oncolytics.%202021;20:556%E2%80%9368." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR50">
<span class="label">50.</span><cite>Zhou R, Yazdanifar M, Roy LD, Whilding LM, Gavrill A, Maher J, Mukherjee P. CAR T cells targeting the tumor MUC1 glycoprotein reduce Triple-Negative breast cancer growth. Front Immunol. 2019;10:1149.
</cite> [<a href="https://doi.org/10.3389/fimmu.2019.01149" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6543840/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31178870/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhou%20R,%20Yazdanifar%20M,%20Roy%20LD,%20Whilding%20LM,%20Gavrill%20A,%20Maher%20J,%20Mukherjee%20P.%20CAR%20T%20cells%20targeting%20the%20tumor%20MUC1%20glycoprotein%20reduce%20Triple-Negative%20breast%20cancer%20growth.%20Front%20Immunol.%202019;10:1149." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR51">
<span class="label">51.</span><cite>Yvon E, Del Vecchio M, Savoldo B, Hoyos V, Dutour A, Anichini A, Dotti G, Brenner MK. Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Research: Official J Am Association Cancer Res. 2009;15(18):5852–60.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-08-3163" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2745508/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19737958/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yvon%20E,%20Del%20Vecchio%20M,%20Savoldo%20B,%20Hoyos%20V,%20Dutour%20A,%20Anichini%20A,%20Dotti%20G,%20Brenner%20MK.%20Immunotherapy%20of%20metastatic%20melanoma%20using%20genetically%20engineered%20GD2-specific%20T%20cells.%20Clin%20Cancer%20Research:%20Official%20J%20Am%20Association%20Cancer%20Res.%202009;15(18):5852%E2%80%9360." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR52">
<span class="label">52.</span><cite>Patel M, Eckburg A, Gantiwala S, Hart Z, Dein J, Lam K, Puri N. Resistance to molecularly targeted therapies in melanoma. Cancers 2021, 13(5).</cite> [<a href="https://doi.org/10.3390/cancers13051115" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7961479/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33807778/" class="usa-link">PubMed</a>]</li>
<li id="CR53">
<span class="label">53.</span><cite>Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, et al. Human epidermal growth factor receptor 2 (HER2) -Specific chimeric antigen receptor-Modified T cells for the immunotherapy of HER2-Positive sarcoma. J Clin Oncology: Official J Am Soc Clin Oncol. 2015;33(15):1688–96.</cite> [<a href="https://doi.org/10.1200/JCO.2014.58.0225" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4429176/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25800760/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ahmed%20N,%20Brawley%20VS,%20Hegde%20M,%20Robertson%20C,%20Ghazi%20A,%20Gerken%20C,%20Liu%20E,%20Dakhova%20O,%20Ashoori%20A,%20Corder%20A,%20et%20al.%20Human%20epidermal%20growth%20factor%20receptor%202%20(HER2)%20-Specific%20chimeric%20antigen%20receptor-Modified%20T%20cells%20for%20the%20immunotherapy%20of%20HER2-Positive%20sarcoma.%20J%20Clin%20Oncology:%20Official%20J%20Am%20Soc%20Clin%20Oncol.%202015;33(15):1688%E2%80%9396." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR54">
<span class="label">54.</span><cite>Papa S, Adami A, Metoudi M, Beatson R, George MS, Achkova D, Williams E, Arif S, Reid F, Elstad M et al. Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study. J Immunother Cancer 2023, 11(6).</cite> [<a href="https://doi.org/10.1136/jitc-2023-007162" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10277526/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37321663/" class="usa-link">PubMed</a>]</li>
<li id="CR55">
<span class="label">55.</span><cite>Montemagno C, Cassim S, Pouyssegur J, Broisat A, Pagès G. From malignant progression to therapeutic targeting: current insights of mesothelin in pancreatic ductal adenocarcinoma. Int J Mol Sci 2020, 21(11).</cite> [<a href="https://doi.org/10.3390/ijms21114067" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7312874/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32517181/" class="usa-link">PubMed</a>]</li>
<li id="CR56">
<span class="label">56.</span><cite>Schoutrop E, El-Serafi I, Poiret T, Zhao Y, Gultekin O, He R, Moyano-Galceran L, Carlson JW, Lehti K, Hassan M, et al. Mesothelin-Specific CAR T cells target ovarian cancer. Cancer Res. 2021;81(11):3022–35.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-20-2701" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33795251/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Schoutrop%20E,%20El-Serafi%20I,%20Poiret%20T,%20Zhao%20Y,%20Gultekin%20O,%20He%20R,%20Moyano-Galceran%20L,%20Carlson%20JW,%20Lehti%20K,%20Hassan%20M,%20et%20al.%20Mesothelin-Specific%20CAR%20T%20cells%20target%20ovarian%20cancer.%20Cancer%20Res.%202021;81(11):3022%E2%80%9335." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR57">
<span class="label">57.</span><cite>Morello A, Sadelain M, Adusumilli PS. Mesothelin-Targeted cars: driving T cells to solid tumors. Cancer Discov. 2016;6(2):133–46.
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-15-0583" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4744527/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26503962/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Morello%20A,%20Sadelain%20M,%20Adusumilli%20PS.%20Mesothelin-Targeted%20cars:%20driving%20T%20cells%20to%20solid%20tumors.%20Cancer%20Discov.%202016;6(2):133%E2%80%9346." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR58">
<span class="label">58.</span><cite>Zhang Z, Jiang D, Yang H, He Z, Liu X, Qin W, Li L, Wang C, Li Y, Li H, et al. Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor. Cell Death Dis. 2019;10(7):476.
</cite> [<a href="https://doi.org/10.1038/s41419-019-1711-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6572851/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31209210/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20Z,%20Jiang%20D,%20Yang%20H,%20He%20Z,%20Liu%20X,%20Qin%20W,%20Li%20L,%20Wang%20C,%20Li%20Y,%20Li%20H,%20et%20al.%20Modified%20CAR%20T%20cells%20targeting%20membrane-proximal%20epitope%20of%20mesothelin%20enhances%20the%20antitumor%20function%20against%20large%20solid%20tumor.%20Cell%20Death%20Dis.%202019;10(7):476." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR59">
<span class="label">59.</span><cite>Schoutrop E, Poiret T, El-Serafi I, Zhao Y, He R, Moter A, Henriksson J, Hassan M, Magalhaes I, Mattsson J. Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models. J Immunother Cancer 2023, 11(2).</cite> [<a href="https://doi.org/10.1136/jitc-2022-005691" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9906404/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36746513/" class="usa-link">PubMed</a>]</li>
<li id="CR60">
<span class="label">60.</span><cite>Zhu Y, Zuo D, Wang K, Lan S, He H, Chen L, Chen X, Feng M. Mesothelin-targeted CAR-T therapy combined with Irinotecan for the treatment of solid cancer. J Cancer Res Clin Oncol. 2023;149(16):15027–38.
</cite> [<a href="https://doi.org/10.1007/s00432-023-05279-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11798019/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37612388/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhu%20Y,%20Zuo%20D,%20Wang%20K,%20Lan%20S,%20He%20H,%20Chen%20L,%20Chen%20X,%20Feng%20M.%20Mesothelin-targeted%20CAR-T%20therapy%20combined%20with%20Irinotecan%20for%20the%20treatment%20of%20solid%20cancer.%20J%20Cancer%20Res%20Clin%20Oncol.%202023;149(16):15027%E2%80%9338." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR61">
<span class="label">61.</span><cite>Ma W, Zhu D, Li J, Chen X, Xie W, Jiang X, Wu L, Wang G, Xiao Y, Liu Z, et al. Coating biomimetic nanoparticles with chimeric antigen receptor T cell-membrane provides high specificity for hepatocellular carcinoma photothermal therapy treatment. Theranostics. 2020;10(3):1281–95.
</cite> [<a href="https://doi.org/10.7150/thno.40291" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6956810/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31938065/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ma%20W,%20Zhu%20D,%20Li%20J,%20Chen%20X,%20Xie%20W,%20Jiang%20X,%20Wu%20L,%20Wang%20G,%20Xiao%20Y,%20Liu%20Z,%20et%20al.%20Coating%20biomimetic%20nanoparticles%20with%20chimeric%20antigen%20receptor%20T%20cell-membrane%20provides%20high%20specificity%20for%20hepatocellular%20carcinoma%20photothermal%20therapy%20treatment.%20Theranostics.%202020;10(3):1281%E2%80%9395." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR62">
<span class="label">62.</span><cite>Kolluri A, Li D, Li N, Duan Z, Roberts LR, Ho M. Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC. Hepatol Commun. 2023;7(2):e0022.
</cite> [<a href="https://doi.org/10.1097/HC9.0000000000000022" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9851680/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36691969/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kolluri%20A,%20Li%20D,%20Li%20N,%20Duan%20Z,%20Roberts%20LR,%20Ho%20M.%20Human%20VH-based%20chimeric%20antigen%20receptor%20T%20cells%20targeting%20glypican%203%20eliminate%20tumors%20in%20preclinical%20models%20of%20HCC.%20Hepatol%20Commun.%202023;7(2):e0022." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR63">
<span class="label">63.</span><cite>Zhang Q, Fu Q, Cao W, Wang H, Xu X, Huang J, Zou A, Zhu J, Wan H, Yao Y, et al. Phase I study of C-CAR031, a GPC3-specific TGFβRIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2024;42(16suppl):4019–4019.</cite> [<a href="https://scholar.google.com/scholar_lookup?Zhang%20Q,%20Fu%20Q,%20Cao%20W,%20Wang%20H,%20Xu%20X,%20Huang%20J,%20Zou%20A,%20Zhu%20J,%20Wan%20H,%20Yao%20Y,%20et%20al.%20Phase%20I%20study%20of%20C-CAR031,%20a%20GPC3-specific%20TGF%CE%B2RIIDN%20armored%20autologous%20CAR-T,%20in%20patients%20with%20advanced%20hepatocellular%20carcinoma%20(HCC).%20J%20Clin%20Oncol.%202024;42(16suppl):4019%E2%80%934019." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR64">
<span class="label">64.</span><cite>Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, Schultz LM, Richards RM, Jiang L, Barsan V, Mancusi R, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022;603(7903):934–41.
</cite> [<a href="https://doi.org/10.1038/s41586-022-04489-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8967714/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35130560/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Majzner%20RG,%20Ramakrishna%20S,%20Yeom%20KW,%20Patel%20S,%20Chinnasamy%20H,%20Schultz%20LM,%20Richards%20RM,%20Jiang%20L,%20Barsan%20V,%20Mancusi%20R,%20et%20al.%20GD2-CAR%20T%20cell%20therapy%20for%20H3K27M-mutated%20diffuse%20midline%20gliomas.%20Nature.%202022;603(7903):934%E2%80%9341." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR65">
<span class="label">65.</span><cite>Zhang G, Zhao Y, Liu Z, Liu W, Wu H, Wang X, Chen Z. GD2 CAR-T cells in combination with nivolumab exhibit enhanced antitumor efficacy. Translational Oncol. 2023;32:101663.</cite> [<a href="https://doi.org/10.1016/j.tranon.2023.101663" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10066552/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36966611/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20G,%20Zhao%20Y,%20Liu%20Z,%20Liu%20W,%20Wu%20H,%20Wang%20X,%20Chen%20Z.%20GD2%20CAR-T%20cells%20in%20combination%20with%20nivolumab%20exhibit%20enhanced%20antitumor%20efficacy.%20Translational%20Oncol.%202023;32:101663." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR66">
<span class="label">66.</span><cite>Quintarelli C, Del Bufalo F, Locatelli F. GD2-CART01 for relapsed or refractory High-Risk neuroblastoma. Reply. N Engl J Med. 2023;388(24):2303–4.
</cite> [<a href="https://doi.org/10.1056/NEJMc2305296" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37314725/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Quintarelli%20C,%20Del%20Bufalo%20F,%20Locatelli%20F.%20GD2-CART01%20for%20relapsed%20or%20refractory%20High-Risk%20neuroblastoma.%20Reply.%20N%20Engl%20J%20Med.%202023;388(24):2303%E2%80%934." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR67">
<span class="label">67.</span><cite>Sun M, Shi H, Liu C, Liu J, Liu X, Sun Y. Construction and evaluation of a novel humanized HER2-specific chimeric receptor. Breast Cancer Research: BCR. 2014;16(3):R61.
</cite> [<a href="https://doi.org/10.1186/bcr3674" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4095682/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24919843/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sun%20M,%20Shi%20H,%20Liu%20C,%20Liu%20J,%20Liu%20X,%20Sun%20Y.%20Construction%20and%20evaluation%20of%20a%20novel%20humanized%20HER2-specific%20chimeric%20receptor.%20Breast%20Cancer%20Research:%20BCR.%202014;16(3):R61." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR68">
<span class="label">68.</span><cite>Yang Y, Sun Q, Deng Z, Shi W, Cheng H. Cbl induced ubiquitination of HER2 mediate immune escape from HER2-targeted CAR-T. J Biochem Mol Toxicol. 2023;37(10):e23446.
</cite> [<a href="https://doi.org/10.1002/jbt.23446" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37354072/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yang%20Y,%20Sun%20Q,%20Deng%20Z,%20Shi%20W,%20Cheng%20H.%20Cbl%20induced%20ubiquitination%20of%20HER2%20mediate%20immune%20escape%20from%20HER2-targeted%20CAR-T.%20J%20Biochem%20Mol%20Toxicol.%202023;37(10):e23446." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR69">
<span class="label">69.</span><cite>Shen L, Li H, Bin S, Li P, Chen J, Gu H, Yuan W. The efficacy of third generation anti–HER2 chimeric antigen receptor T cells in combination with PD1 Blockade against malignant glioblastoma cells. Oncol Rep. 2019;42(4):1549–57.
</cite> [<a href="https://doi.org/10.3892/or.2019.7263" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31524276/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shen%20L,%20Li%20H,%20Bin%20S,%20Li%20P,%20Chen%20J,%20Gu%20H,%20Yuan%20W.%20The%20efficacy%20of%20third%20generation%20anti%E2%80%93HER2%20chimeric%20antigen%20receptor%20T%20cells%20in%20combination%20with%20PD1%20Blockade%20against%20malignant%20glioblastoma%20cells.%20Oncol%20Rep.%202019;42(4):1549%E2%80%9357." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR70">
<span class="label">70.</span><cite>Hegde M, Joseph SK, Pashankar F, DeRenzo C, Sanber K, Navai S, Byrd TT, Hicks J, Xu ML, Gerken C, et al. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nat Commun. 2020;11(1):3549.
</cite> [<a href="https://doi.org/10.1038/s41467-020-17175-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7363864/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32669548/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hegde%20M,%20Joseph%20SK,%20Pashankar%20F,%20DeRenzo%20C,%20Sanber%20K,%20Navai%20S,%20Byrd%20TT,%20Hicks%20J,%20Xu%20ML,%20Gerken%20C,%20et%20al.%20Tumor%20response%20and%20endogenous%20immune%20reactivity%20after%20administration%20of%20HER2%20CAR%20T%20cells%20in%20a%20child%20with%20metastatic%20rhabdomyosarcoma.%20Nat%20Commun.%202020;11(1):3549." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR71">
<span class="label">71.</span><cite>Hegde M, Navai S, DeRenzo C, Joseph SK, Sanber K, Wu M, Gad AZ, Janeway KA, Campbell M, Mullikin D, et al. Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat Cancer. 2024;5(6):880–94.
</cite> [<a href="https://doi.org/10.1038/s43018-024-00749-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11588040/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38658775/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hegde%20M,%20Navai%20S,%20DeRenzo%20C,%20Joseph%20SK,%20Sanber%20K,%20Wu%20M,%20Gad%20AZ,%20Janeway%20KA,%20Campbell%20M,%20Mullikin%20D,%20et%20al.%20Autologous%20HER2-specific%20CAR%20T%20cells%20after%20lymphodepletion%20for%20advanced%20sarcoma:%20a%20phase%201%20trial.%20Nat%20Cancer.%202024;5(6):880%E2%80%9394." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR72">
<span class="label">72.</span><cite>Hammarström S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Sem Cancer Biol. 1999;9(2):67–81.</cite> [<a href="https://doi.org/10.1006/scbi.1998.0119" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10202129/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hammarstr%C3%B6m%20S.%20The%20carcinoembryonic%20antigen%20(CEA)%20family:%20structures,%20suggested%20functions%20and%20expression%20in%20normal%20and%20malignant%20tissues.%20Sem%20Cancer%20Biol.%201999;9(2):67%E2%80%9381." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR73">
<span class="label">73.</span><cite>Zhang C, Wang L, Zhang Q, Shen J, Huang X, Wang M, Huang Y, Chen J, Xu Y, Zhao W, et al. Screening and characterization of the ScFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma. Front Immunol. 2023;14:1182409.
</cite> [<a href="https://doi.org/10.3389/fimmu.2023.1182409" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10248079/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37304295/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20C,%20Wang%20L,%20Zhang%20Q,%20Shen%20J,%20Huang%20X,%20Wang%20M,%20Huang%20Y,%20Chen%20J,%20Xu%20Y,%20Zhao%20W,%20et%20al.%20Screening%20and%20characterization%20of%20the%20ScFv%20for%20chimeric%20antigen%20receptor%20T%20cells%20targeting%20CEA-positive%20carcinoma.%20Front%20Immunol.%202023;14:1182409." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR74">
<span class="label">74.</span><cite>Sato O, Tsuchikawa T, Kato T, Amaishi Y, Okamoto S, Mineno J, Takeuchi Y, Sasaki K, Nakamura T, Umemoto K et al. Tumor growth suppression of pancreatic cancer orthotopic xenograft model by CEA-Targeting CAR-T cells. Cancers 2023, 15(3).</cite> [<a href="https://doi.org/10.3390/cancers15030601" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9913141/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36765558/" class="usa-link">PubMed</a>]</li>
<li id="CR75">
<span class="label">75.</span><cite>Zhang Y, Tacheva-Grigorova SK, Sutton J, Melton Z, Mak YSL, Lay C, Smith BA, Sai T, Van Blarcom T, Sasu BJ, et al. Allogeneic CAR T cells targeting DLL3 are efficacious and safe in preclinical models of small cell lung cancer. Clin Cancer Research: Official J Am Association Cancer Res. 2023;29(5):971–85.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-22-2293" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36692420/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20Y,%20Tacheva-Grigorova%20SK,%20Sutton%20J,%20Melton%20Z,%20Mak%20YSL,%20Lay%20C,%20Smith%20BA,%20Sai%20T,%20Van%20Blarcom%20T,%20Sasu%20BJ,%20et%20al.%20Allogeneic%20CAR%20T%20cells%20targeting%20DLL3%20are%20efficacious%20and%20safe%20in%20preclinical%20models%20of%20small%20cell%20lung%20cancer.%20Clin%20Cancer%20Research:%20Official%20J%20Am%20Association%20Cancer%20Res.%202023;29(5):971%E2%80%9385." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR76">
<span class="label">76.</span><cite>Jaspers JE, Khan JF, Godfrey WD, Lopez AV, Ciampricotti M, Rudin CM, Brentjens RJ. IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. J Clin Investig 2023, 133(9).</cite> [<a href="https://doi.org/10.1172/JCI166028" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10145930/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36951942/" class="usa-link">PubMed</a>]</li>
<li id="CR77">
<span class="label">77.</span><cite>Zhou D, Byers LA, Sable B, Smit MD, Sadraei NH, Dutta S, Upreti VV. Clinical Pharmacology profile of AMG 119, the first chimeric antigen receptor T (CAR-T) cell therapy targeting Delta-Like ligand 3 (DLL3), in patients with relapsed/refractory small cell lung cancer (SCLC). J Clin Pharmacol. 2024;64(3):362–70.
</cite> [<a href="https://doi.org/10.1002/jcph.2346" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37694295/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhou%20D,%20Byers%20LA,%20Sable%20B,%20Smit%20MD,%20Sadraei%20NH,%20Dutta%20S,%20Upreti%20VV.%20Clinical%20Pharmacology%20profile%20of%20AMG%20119,%20the%20first%20chimeric%20antigen%20receptor%20T%20(CAR-T)%20cell%20therapy%20targeting%20Delta-Like%20ligand%203%20(DLL3),%20in%20patients%20with%20relapsed/refractory%20small%20cell%20lung%20cancer%20(SCLC).%20J%20Clin%20Pharmacol.%202024;64(3):362%E2%80%9370." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR78">
<span class="label">78.</span><cite>Lisby AN, Flickinger JC Jr., Bashir B, Weindorfer M, Shelukar S, Crutcher M, Snook AE, Waldman SA. GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. Expert Rev Precision Med Drug Dev. 2021;6(2):117–29.</cite> [<a href="https://doi.org/10.1080/23808993.2021.1876518" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8133521/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34027103/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lisby%20AN,%20Flickinger%20JC%20Jr.,%20Bashir%20B,%20Weindorfer%20M,%20Shelukar%20S,%20Crutcher%20M,%20Snook%20AE,%20Waldman%20SA.%20GUCY2C%20as%20a%20biomarker%20to%20target%20precision%20therapies%20for%20patients%20with%20colorectal%20cancer.%20Expert%20Rev%20Precision%20Med%20Drug%20Dev.%202021;6(2):117%E2%80%9329." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR79">
<span class="label">79.</span><cite>Baybutt T, Snook A, Waldman S, Stem J, Caparosa E, Zalewski A. 105 A third-generation human GUCY2C-targeted CAR-T cell for colorectal cancer immunotherapy. J Immunother Cancer. 2020;8:A116–116.</cite> [<a href="https://scholar.google.com/scholar_lookup?Baybutt%20T,%20Snook%20A,%20Waldman%20S,%20Stem%20J,%20Caparosa%20E,%20Zalewski%20A.%20105%20A%20third-generation%20human%20GUCY2C-targeted%20CAR-T%20cell%20for%20colorectal%20cancer%20immunotherapy.%20J%20Immunother%20Cancer.%202020;8:A116%E2%80%93116." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR80">
<span class="label">80.</span><cite>Qi C, Liu C, Li J, Gong J, Wang X, Wang Z, Lu X-a, He T, Ding Y, Wu F, et al. Phase I study of GUCY2C CAR-T therapy IM96 in patients with metastatic colorectal cancer. J Clin Oncol. 2024;42(16suppl):2518–2518.</cite> [<a href="https://scholar.google.com/scholar_lookup?Qi%20C,%20Liu%20C,%20Li%20J,%20Gong%20J,%20Wang%20X,%20Wang%20Z,%20Lu%20X-a,%20He%20T,%20Ding%20Y,%20Wu%20F,%20et%20al.%20Phase%20I%20study%20of%20GUCY2C%20CAR-T%20therapy%20IM96%20in%20patients%20with%20metastatic%20colorectal%20cancer.%20J%20Clin%20Oncol.%202024;42(16suppl):2518%E2%80%932518." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR81">
<span class="label">81.</span><cite>Chen N, Pu C, Zhao L, Li W, Wang C, Zhu R, Liang T, Niu C, Huang X, Tang H, et al. Chimeric antigen receptor T cells targeting CD19 and GCC in metastatic colorectal cancer: A nonrandomized clinical trial. JAMA Oncol. 2024;10(11):1532–6.
</cite> [<a href="https://doi.org/10.1001/jamaoncol.2024.3891" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11413756/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39298141/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20N,%20Pu%20C,%20Zhao%20L,%20Li%20W,%20Wang%20C,%20Zhu%20R,%20Liang%20T,%20Niu%20C,%20Huang%20X,%20Tang%20H,%20et%20al.%20Chimeric%20antigen%20receptor%20T%20cells%20targeting%20CD19%20and%20GCC%20in%20metastatic%20colorectal%20cancer:%20A%20nonrandomized%20clinical%20trial.%20JAMA%20Oncol.%202024;10(11):1532%E2%80%936." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR82">
<span class="label">82.</span><cite>Friedlaender A, Subbiah V, Russo A, Banna GL, Malapelle U, Rolfo C, Addeo A. EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. Nat Reviews Clin Oncol. 2022;19(1):51–69.</cite> [<a href="https://doi.org/10.1038/s41571-021-00558-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34561632/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Friedlaender%20A,%20Subbiah%20V,%20Russo%20A,%20Banna%20GL,%20Malapelle%20U,%20Rolfo%20C,%20Addeo%20A.%20EGFR%20and%20HER2%20exon%2020%20insertions%20in%20solid%20tumours:%20from%20biology%20to%20treatment.%20Nat%20Reviews%20Clin%20Oncol.%202022;19(1):51%E2%80%9369." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR83">
<span class="label">83.</span><cite>Li G, Guo J, Zheng Y, Ding W, Han Z, Qin L, Mo W, Luo M. CXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cells. Mol Therapy Oncolytics. 2021;22:507–17.</cite> [<a href="https://doi.org/10.1016/j.omto.2021.07.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8433065/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34553036/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20G,%20Guo%20J,%20Zheng%20Y,%20Ding%20W,%20Han%20Z,%20Qin%20L,%20Mo%20W,%20Luo%20M.%20CXCR5%20guides%20migration%20and%20tumor%20eradication%20of%20anti-EGFR%20chimeric%20antigen%20receptor%20T%20cells.%20Mol%20Therapy%20Oncolytics.%202021;22:507%E2%80%9317." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR84">
<span class="label">84.</span><cite>Li G, Liao G, Xie J, Liu B, Li X, Qiu M. Overexpression of SMAD7 improves the function of EGFR-targeted human CAR-T cells against non-small-cell lung cancer. Respirol (Carlton Vic). 2023;28(9):869–80.</cite> [<a href="https://doi.org/10.1111/resp.14541" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37376985/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20G,%20Liao%20G,%20Xie%20J,%20Liu%20B,%20Li%20X,%20Qiu%20M.%20Overexpression%20of%20SMAD7%20improves%20the%20function%20of%20EGFR-targeted%20human%20CAR-T%20cells%20against%20non-small-cell%20lung%20cancer.%20Respirol%20(Carlton%20Vic).%202023;28(9):869%E2%80%9380." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR85">
<span class="label">85.</span><cite>Jiang W, Li T, Guo J, Wang J, Jia L, Shi X, Yang T, Jiao R, Wei X, Feng Z, et al. Bispecific c-Met/PD-L1 CAR-T cells have enhanced therapeutic effects on hepatocellular carcinoma. Front Oncol. 2021;11:546586.
</cite> [<a href="https://doi.org/10.3389/fonc.2021.546586" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7987916/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33777728/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jiang%20W,%20Li%20T,%20Guo%20J,%20Wang%20J,%20Jia%20L,%20Shi%20X,%20Yang%20T,%20Jiao%20R,%20Wei%20X,%20Feng%20Z,%20et%20al.%20Bispecific%20c-Met/PD-L1%20CAR-T%20cells%20have%20enhanced%20therapeutic%20effects%20on%20hepatocellular%20carcinoma.%20Front%20Oncol.%202021;11:546586." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR86">
<span class="label">86.</span><cite>Li K, Qian S, Huang M, Chen M, Peng L, Liu J, Xu W, Xu J. Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy. Am J Translational Res. 2021;13(1):156–67.</cite> [<a href="/articles/PMC7847509/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33527015/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20K,%20Qian%20S,%20Huang%20M,%20Chen%20M,%20Peng%20L,%20Liu%20J,%20Xu%20W,%20Xu%20J.%20Development%20of%20GPC3%20and%20EGFR-dual-targeting%20chimeric%20antigen%20receptor-T%20cells%20for%20adoptive%20T%20cell%20therapy.%20Am%20J%20Translational%20Res.%202021;13(1):156%E2%80%9367." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR87">
<span class="label">87.</span><cite>Rennert P, Wu L, Su L, Lobb R, Ambrose C. 160 evaluation and development of dual and triple antigen targeting CAR-T engager proteins for Her2-positive CNS metastases and solid tumors. J Immunother Cancer. 2021;9:A170–170.</cite> [<a href="https://scholar.google.com/scholar_lookup?Rennert%20P,%20Wu%20L,%20Su%20L,%20Lobb%20R,%20Ambrose%20C.%20160%20evaluation%20and%20development%20of%20dual%20and%20triple%20antigen%20targeting%20CAR-T%20engager%20proteins%20for%20Her2-positive%20CNS%20metastases%20and%20solid%20tumors.%20J%20Immunother%20Cancer.%202021;9:A170%E2%80%93170." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR88">
<span class="label">88.</span><cite>Huang R, Li X, He Y, Zhu W, Gao L, Liu Y, Gao L, Wen Q, Zhong JF, Zhang C, et al. Recent advances in CAR-T cell engineering. J Hematol Oncol. 2020;13(1):86.
</cite> [<a href="https://doi.org/10.1186/s13045-020-00910-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7333410/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32616000/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Huang%20R,%20Li%20X,%20He%20Y,%20Zhu%20W,%20Gao%20L,%20Liu%20Y,%20Gao%20L,%20Wen%20Q,%20Zhong%20JF,%20Zhang%20C,%20et%20al.%20Recent%20advances%20in%20CAR-T%20cell%20engineering.%20J%20Hematol%20Oncol.%202020;13(1):86." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR89">
<span class="label">89.</span><cite>Yan P, Dong Y, Zhang F, Zhen T, Liang J, Shi H, Han A. Claudin18.2 expression and its clinicopathological feature in adenocarcinoma from various parts. J Clin Pathol 2024.</cite> [<a href="https://doi.org/10.1136/jcp-2023-209268" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38548320/" class="usa-link">PubMed</a>]</li>
<li id="CR90">
<span class="label">90.</span><cite>Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, Zhang M, Peng Z, Zhou J, Cao Y, et al. Claudin18.2-specific CAR T cells in Gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28(6):1189–98.
</cite> [<a href="https://doi.org/10.1038/s41591-022-01800-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9205778/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35534566/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Qi%20C,%20Gong%20J,%20Li%20J,%20Liu%20D,%20Qin%20Y,%20Ge%20S,%20Zhang%20M,%20Peng%20Z,%20Zhou%20J,%20Cao%20Y,%20et%20al.%20Claudin18.2-specific%20CAR%20T%20cells%20in%20Gastrointestinal%20cancers:%20phase%201%20trial%20interim%20results.%20Nat%20Med.%202022;28(6):1189%E2%80%9398." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR91">
<span class="label">91.</span><cite>Qi C, Zhang P, Liu C, Zhang J, Zhou J, Yuan J, Liu D, Zhang M, Gong J, Wang X, et al. Safety and efficacy of CT041 in patients with refractory metastatic pancreatic cancer: A pooled analysis of two Early-Phase trials. J Clin Oncology: Official J Am Soc Clin Oncol. 2024;42(21):2565–77.</cite> [<a href="https://doi.org/10.1200/JCO.23.02314" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38788174/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Qi%20C,%20Zhang%20P,%20Liu%20C,%20Zhang%20J,%20Zhou%20J,%20Yuan%20J,%20Liu%20D,%20Zhang%20M,%20Gong%20J,%20Wang%20X,%20et%20al.%20Safety%20and%20efficacy%20of%20CT041%20in%20patients%20with%20refractory%20metastatic%20pancreatic%20cancer:%20A%20pooled%20analysis%20of%20two%20Early-Phase%20trials.%20J%20Clin%20Oncology:%20Official%20J%20Am%20Soc%20Clin%20Oncol.%202024;42(21):2565%E2%80%9377." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR92">
<span class="label">92.</span><cite>Qi C, Liu C, Gong J, Liu D, Wang X, Zhang P, Qin Y, Ge S, Zhang M, Peng Z, et al. Claudin18.2-specific CAR T cells in Gastrointestinal cancers: phase 1 trial final results. Nat Med. 2024;30(8):2224–34.
</cite> [<a href="https://doi.org/10.1038/s41591-024-03037-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38830992/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Qi%20C,%20Liu%20C,%20Gong%20J,%20Liu%20D,%20Wang%20X,%20Zhang%20P,%20Qin%20Y,%20Ge%20S,%20Zhang%20M,%20Peng%20Z,%20et%20al.%20Claudin18.2-specific%20CAR%20T%20cells%20in%20Gastrointestinal%20cancers:%20phase%201%20trial%20final%20results.%20Nat%20Med.%202024;30(8):2224%E2%80%9334." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR93">
<span class="label">93.</span><cite>Gagelmann N, Riecken K, Wolschke C, Berger C, Ayuk FA, Fehse B, Kröger N. Development of CAR-T cell therapies for multiple myeloma. Leukemia. 2020;34(9):2317–32.
</cite> [<a href="https://doi.org/10.1038/s41375-020-0930-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32572190/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gagelmann%20N,%20Riecken%20K,%20Wolschke%20C,%20Berger%20C,%20Ayuk%20FA,%20Fehse%20B,%20Kr%C3%B6ger%20N.%20Development%20of%20CAR-T%20cell%20therapies%20for%20multiple%20myeloma.%20Leukemia.%202020;34(9):2317%E2%80%9332." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR94">
<span class="label">94.</span><cite>O’Neal J, Ritchey JK, Cooper ML, Niswonger J, Sofía González L, Street E, Rettig MP, Gladney SW, Gehrs L, Abboud R, et al. CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8 + CS1 expressing CAR-T cells. Leukemia. 2022;36(6):1625–34.
</cite> [<a href="https://doi.org/10.1038/s41375-022-01559-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9162922/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35422095/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?O%E2%80%99Neal%20J,%20Ritchey%20JK,%20Cooper%20ML,%20Niswonger%20J,%20Sof%C3%ADa%20Gonz%C3%A1lez%20L,%20Street%20E,%20Rettig%20MP,%20Gladney%20SW,%20Gehrs%20L,%20Abboud%20R,%20et%20al.%20CS1%20CAR-T%20targeting%20the%20distal%20domain%20of%20CS1%20(SLAMF7)%20shows%20efficacy%20in%20high%20tumor%20burden%20myeloma%20model%20despite%20fratricide%20of%20CD8%E2%80%89+%E2%80%89CS1%20expressing%20CAR-T%20cells.%20Leukemia.%202022;36(6):1625%E2%80%9334." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR95">
<span class="label">95.</span><cite>Petrovic K, Robinson J, Whitworth K, Jinks E, Shaaban A, Lee SP. TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo. PLoS ONE. 2019;14(10):e0224015.
</cite> [<a href="https://doi.org/10.1371/journal.pone.0224015" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6797195/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31622431/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Petrovic%20K,%20Robinson%20J,%20Whitworth%20K,%20Jinks%20E,%20Shaaban%20A,%20Lee%20SP.%20TEM8/ANTXR1-specific%20CAR%20T%20cells%20mediate%20toxicity%20in%20vivo.%20PLoS%20ONE.%202019;14(10):e0224015." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR96">
<span class="label">96.</span><cite>Posey AD Jr., Schwab RD, Boesteanu AC, Steentoft C, Mandel U, Engels B, Stone JD, Madsen TD, Schreiber K, Haines KM, et al. Engineered CAR T cells targeting the Cancer-Associated Tn-Glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity. 2016;44(6):1444–54.
</cite> [<a href="https://doi.org/10.1016/j.immuni.2016.05.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5358667/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27332733/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Posey%20AD%20Jr.,%20Schwab%20RD,%20Boesteanu%20AC,%20Steentoft%20C,%20Mandel%20U,%20Engels%20B,%20Stone%20JD,%20Madsen%20TD,%20Schreiber%20K,%20Haines%20KM,%20et%20al.%20Engineered%20CAR%20T%20cells%20targeting%20the%20Cancer-Associated%20Tn-Glycoform%20of%20the%20membrane%20mucin%20MUC1%20control%20adenocarcinoma.%20Immunity.%202016;44(6):1444%E2%80%9354." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR97">
<span class="label">97.</span><cite>Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a sweet success? Front Med. 2022;16(3):322–38.
</cite> [<a href="https://doi.org/10.1007/s11684-021-0901-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35687277/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Safarzadeh%20Kozani%20P,%20Safarzadeh%20Kozani%20P,%20Rahbarizadeh%20F.%20CAR%20T%20cells%20redirected%20against%20tumor-specific%20antigen%20glycoforms:%20can%20low-sugar%20antigens%20guarantee%20a%20sweet%20success?%20Front%20Med.%202022;16(3):322%E2%80%9338." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR98">
<span class="label">98.</span><cite>Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL, Abou-El-Enein M. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Reviews Clin Oncol. 2023;20(1):49–62.</cite> [<a href="https://doi.org/10.1038/s41571-022-00704-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10278599/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36418477/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Flugel%20CL,%20Majzner%20RG,%20Krenciute%20G,%20Dotti%20G,%20Riddell%20SR,%20Wagner%20DL,%20Abou-El-Enein%20M.%20Overcoming%20on-target,%20off-tumour%20toxicity%20of%20CAR%20T%20cell%20therapy%20for%20solid%20tumours.%20Nat%20Reviews%20Clin%20Oncol.%202023;20(1):49%E2%80%9362." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR99">
<span class="label">99.</span><cite>Guzman G, Pellot K, Reed MR, Rodriguez A. CAR T-cells to treat brain tumors. Brain Res Bull. 2023;196:76–98.
</cite> [<a href="https://doi.org/10.1016/j.brainresbull.2023.02.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36841424/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Guzman%20G,%20Pellot%20K,%20Reed%20MR,%20Rodriguez%20A.%20CAR%20T-cells%20to%20treat%20brain%20tumors.%20Brain%20Res%20Bull.%202023;196:76%E2%80%9398." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR100">
<span class="label">100.</span><cite>Rodriguez A, Brown C, Badie B. Chimeric antigen receptor T-cell therapy for glioblastoma. Translational Research: J Lab Clin Med. 2017;187:93–102.</cite> [<a href="https://doi.org/10.1016/j.trsl.2017.07.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28755873/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rodriguez%20A,%20Brown%20C,%20Badie%20B.%20Chimeric%20antigen%20receptor%20T-cell%20therapy%20for%20glioblastoma.%20Translational%20Research:%20J%20Lab%20Clin%20Med.%202017;187:93%E2%80%93102." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR101">
<span class="label">101.</span><cite>Akhavan D, Alizadeh D, Wang D, Weist MR, Shepphird JK, Brown CE. CAR T cells for brain tumors: lessons learned and road ahead. Immunol Rev. 2019;290(1):60–84.
</cite> [<a href="https://doi.org/10.1111/imr.12773" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6771592/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31355493/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Akhavan%20D,%20Alizadeh%20D,%20Wang%20D,%20Weist%20MR,%20Shepphird%20JK,%20Brown%20CE.%20CAR%20T%20cells%20for%20brain%20tumors:%20lessons%20learned%20and%20road%20ahead.%20Immunol%20Rev.%202019;290(1):60%E2%80%9384." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR102">
<span class="label">102.</span><cite>Huang J, Li YB, Charlebois C, Nguyen T, Liu Z, Bloemberg D, Zafer A, Baumann E, Sodja C, Leclerc S, et al. Application of blood brain barrier models in pre-clinical assessment of glioblastoma-targeting CAR-T based immunotherapies. Fluids Barriers CNS. 2022;19(1):38.
</cite> [<a href="https://doi.org/10.1186/s12987-022-00342-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9161615/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35650594/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Huang%20J,%20Li%20YB,%20Charlebois%20C,%20Nguyen%20T,%20Liu%20Z,%20Bloemberg%20D,%20Zafer%20A,%20Baumann%20E,%20Sodja%20C,%20Leclerc%20S,%20et%20al.%20Application%20of%20blood%20brain%20barrier%20models%20in%20pre-clinical%20assessment%20of%20glioblastoma-targeting%20CAR-T%20based%20immunotherapies.%20Fluids%20Barriers%20CNS.%202022;19(1):38." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR103">
<span class="label">103.</span><cite>Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI, Harrington K, Williamson P, Moeendarbary E, Charras G, et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol. 2013;15(6):637–46.
</cite> [<a href="https://doi.org/10.1038/ncb2756" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3836234/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23708000/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Calvo%20F,%20Ege%20N,%20Grande-Garcia%20A,%20Hooper%20S,%20Jenkins%20RP,%20Chaudhry%20SI,%20Harrington%20K,%20Williamson%20P,%20Moeendarbary%20E,%20Charras%20G,%20et%20al.%20Mechanotransduction%20and%20YAP-dependent%20matrix%20remodelling%20is%20required%20for%20the%20generation%20and%20maintenance%20of%20cancer-associated%20fibroblasts.%20Nat%20Cell%20Biol.%202013;15(6):637%E2%80%9346." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR104">
<span class="label">104.</span><cite>Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8(10):1219–26.
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-18-0442" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30135176/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Majzner%20RG,%20Mackall%20CL.%20Tumor%20antigen%20escape%20from%20CAR%20T-cell%20therapy.%20Cancer%20Discov.%202018;8(10):1219%E2%80%9326." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR105">
<span class="label">105.</span><cite>Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS, Corder A, Schönfeld K, Koch J, Dotti G, et al. TanCAR: A novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Therapy Nucleic Acids. 2013;2(7):e105.
</cite> [<a href="https://doi.org/10.1038/mtna.2013.32" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3731887/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23839099/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Grada%20Z,%20Hegde%20M,%20Byrd%20T,%20Shaffer%20DR,%20Ghazi%20A,%20Brawley%20VS,%20Corder%20A,%20Sch%C3%B6nfeld%20K,%20Koch%20J,%20Dotti%20G,%20et%20al.%20TanCAR:%20A%20novel%20bispecific%20chimeric%20antigen%20receptor%20for%20cancer%20immunotherapy.%20Mol%20Therapy%20Nucleic%20Acids.%202013;2(7):e105." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR106">
<span class="label">106.</span><cite>Jiang Y, Wen W, Yang F, Han D, Zhang W, Qin W. Prospect of prostate cancer treatment: armed CAR-T or combination therapy. Cancers 2022, 14(4).</cite> [<a href="https://doi.org/10.3390/cancers14040967" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8869943/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35205714/" class="usa-link">PubMed</a>]</li>
<li id="CR107">
<span class="label">107.</span><cite>Slaney CY, Kershaw MH, Darcy PK. Trafficking of T cells into tumors. Cancer Res. 2014;74(24):7168–74.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-14-2458" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25477332/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Slaney%20CY,%20Kershaw%20MH,%20Darcy%20PK.%20Trafficking%20of%20T%20cells%20into%20tumors.%20Cancer%20Res.%202014;74(24):7168%E2%80%9374." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR108">
<span class="label">108.</span><cite>Chen W, Li Y, Liu C, Kang Y, Qin D, Chen S, Zhou J, Liu HJ, Ferdows BE, Patel DN, et al. (β-Elemene@Stanene) strategy for enhanced cancer Chemo-Immunotherapy. Angewandte Chemie (International Ed English). 2023;62(41):e202308413. situ Engineering of Tumor-Associated Macrophages via a Nanodrug-Delivering-Drug.</cite> [<a href="https://doi.org/10.1002/anie.202308413" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37380606/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20W,%20Li%20Y,%20Liu%20C,%20Kang%20Y,%20Qin%20D,%20Chen%20S,%20Zhou%20J,%20Liu%20HJ,%20Ferdows%20BE,%20Patel%20DN,%20et%20al.%20(%CE%B2-Elemene@Stanene)%20strategy%20for%20enhanced%20cancer%20Chemo-Immunotherapy.%20Angewandte%20Chemie%20(International%20Ed%20English).%202023;62(41):e202308413.%20situ%20Engineering%20of%20Tumor-Associated%20Macrophages%20via%20a%20Nanodrug-Delivering-Drug." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR109">
<span class="label">109.</span><cite>Huang R, Zhu J, Fan R, Tang Y, Hu L, Lee H, Chen S. Extracellular vesicle-based drug delivery systems in cancer. Extracell Vesicle. 2024;4:100053.</cite> [<a href="https://scholar.google.com/scholar_lookup?Huang%20R,%20Zhu%20J,%20Fan%20R,%20Tang%20Y,%20Hu%20L,%20Lee%20H,%20Chen%20S.%20Extracellular%20vesicle-based%20drug%20delivery%20systems%20in%20cancer.%20Extracell%20Vesicle.%202024;4:100053." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR110">
<span class="label">110.</span><cite>Johnson A, Townsend M, O’Neill K. Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors. <em>Cells</em> 2022, 11(22).</cite> [<a href="https://doi.org/10.3390/cells11223626" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9688327/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36429054/" class="usa-link">PubMed</a>]</li>
<li id="CR111">
<span class="label">111.</span><cite>Kaushik S, Pickup MW, Weaver VM. From transformation to metastasis: deconstructing the extracellular matrix in breast cancer. Cancer Metastasis Rev. 2016;35(4):655–67.
</cite> [<a href="https://doi.org/10.1007/s10555-016-9650-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5215979/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27914000/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kaushik%20S,%20Pickup%20MW,%20Weaver%20VM.%20From%20transformation%20to%20metastasis:%20deconstructing%20the%20extracellular%20matrix%20in%20breast%20cancer.%20Cancer%20Metastasis%20Rev.%202016;35(4):655%E2%80%9367." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR112">
<span class="label">112.</span><cite>Ai L, Chen J, Yan H, He Q, Luo P, Xu Z, Yang X. Research status and outlook of PD-1/PD-L1 inhibitors for cancer therapy. Drug Des Devel Ther. 2020;14:3625–49.
</cite> [<a href="https://doi.org/10.2147/DDDT.S267433" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7490077/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32982171/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ai%20L,%20Chen%20J,%20Yan%20H,%20He%20Q,%20Luo%20P,%20Xu%20Z,%20Yang%20X.%20Research%20status%20and%20outlook%20of%20PD-1/PD-L1%20inhibitors%20for%20cancer%20therapy.%20Drug%20Des%20Devel%20Ther.%202020;14:3625%E2%80%9349." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR113">
<span class="label">113.</span><cite>Wang Z, Han W. Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomark Res. 2018;6:4.
</cite> [<a href="https://doi.org/10.1186/s40364-018-0116-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5778792/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29387417/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20Z,%20Han%20W.%20Biomarkers%20of%20cytokine%20release%20syndrome%20and%20neurotoxicity%20related%20to%20CAR-T%20cell%20therapy.%20Biomark%20Res.%202018;6:4." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR114">
<span class="label">114.</span><cite>Lee K, Paek H, Ai L, Liu Z, Jin L, Li M, Jun T, Higashi MK, Onel K, Oh WK, et al. Treatment profile of CAR-T cell therapy induced cytokine release syndrome and neurotoxicity: insights from Real-World evidence. Blood. 2022;140(Supplement 1):12750–2.</cite> [<a href="https://scholar.google.com/scholar_lookup?Lee%20K,%20Paek%20H,%20Ai%20L,%20Liu%20Z,%20Jin%20L,%20Li%20M,%20Jun%20T,%20Higashi%20MK,%20Onel%20K,%20Oh%20WK,%20et%20al.%20Treatment%20profile%20of%20CAR-T%20cell%20therapy%20induced%20cytokine%20release%20syndrome%20and%20neurotoxicity:%20insights%20from%20Real-World%20evidence.%20Blood.%202022;140(Supplement%201):12750%E2%80%932." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR115">
<span class="label">115.</span><cite>Sterner RC, Sterner RM. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy. Front Immunol. 2022;13:879608.
</cite> [<a href="https://doi.org/10.3389/fimmu.2022.879608" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9445841/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36081506/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sterner%20RC,%20Sterner%20RM.%20Immune%20effector%20cell%20associated%20neurotoxicity%20syndrome%20in%20chimeric%20antigen%20receptor-T%20cell%20therapy.%20Front%20Immunol.%202022;13:879608." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR116">
<span class="label">116.</span><cite>Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, Yeung C, Liles WC, Wurfel M, Lopez JA, et al. Endothelial activation and Blood-Brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7(12):1404–19.
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-17-0698" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5718945/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29025771/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gust%20J,%20Hay%20KA,%20Hanafi%20LA,%20Li%20D,%20Myerson%20D,%20Gonzalez-Cuyar%20LF,%20Yeung%20C,%20Liles%20WC,%20Wurfel%20M,%20Lopez%20JA,%20et%20al.%20Endothelial%20activation%20and%20Blood-Brain%20barrier%20disruption%20in%20neurotoxicity%20after%20adoptive%20immunotherapy%20with%20CD19%20CAR-T%20cells.%20Cancer%20Discov.%202017;7(12):1404%E2%80%9319." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR117">
<span class="label">117.</span><cite>Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, Halton E, Wang X, Senechal B, Purdon T, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8(8):958–71.
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-17-1319" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6385599/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29880584/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Santomasso%20BD,%20Park%20JH,%20Salloum%20D,%20Riviere%20I,%20Flynn%20J,%20Mead%20E,%20Halton%20E,%20Wang%20X,%20Senechal%20B,%20Purdon%20T,%20et%20al.%20Clinical%20and%20biological%20correlates%20of%20neurotoxicity%20associated%20with%20CAR%20T-cell%20therapy%20in%20patients%20with%20B-cell%20acute%20lymphoblastic%20leukemia.%20Cancer%20Discov.%202018;8(8):958%E2%80%9371." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR118">
<span class="label">118.</span><cite>Xiong X, Yu Y, Jin X, Xie D, Sun R, Lu W, Wei Y, Guo R, Zhao M. Functional validation of the RQR8 suicide /Marker gene in CD19 CAR-T cells and CLL1CAR-T cells. Ann Hematol. 2023;102(6):1523–35.
</cite> [<a href="https://doi.org/10.1007/s00277-023-05227-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37086278/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xiong%20X,%20Yu%20Y,%20Jin%20X,%20Xie%20D,%20Sun%20R,%20Lu%20W,%20Wei%20Y,%20Guo%20R,%20Zhao%20M.%20Functional%20validation%20of%20the%20RQR8%20suicide%20/Marker%20gene%20in%20CD19%20CAR-T%20cells%20and%20CLL1CAR-T%20cells.%20Ann%20Hematol.%202023;102(6):1523%E2%80%9335." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR119">
<span class="label">119.</span><cite>Chen S, Li Y, Zhou Z, Saiding Q, Zhang Y, An S, Khan MM, Ji X, Qiao R, Tao W, et al. Macrophage hitchhiking nanomedicine for enhanced β-elemene delivery and tumor therapy. Sci Adv. 2025;11(21):eadw7191.
</cite> [<a href="https://doi.org/10.1126/sciadv.adw7191" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12094207/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40397726/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20S,%20Li%20Y,%20Zhou%20Z,%20Saiding%20Q,%20Zhang%20Y,%20An%20S,%20Khan%20MM,%20Ji%20X,%20Qiao%20R,%20Tao%20W,%20et%20al.%20Macrophage%20hitchhiking%20nanomedicine%20for%20enhanced%20%CE%B2-elemene%20delivery%20and%20tumor%20therapy.%20Sci%20Adv.%202025;11(21):eadw7191." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR120">
<span class="label">120.</span><cite>Chen S, Huang X, Xue Y, Álvarez-Benedicto E, Shi Y, Chen W, Koo S, Siegwart DJ, Dong Y, Tao W. Nanotechnology-based mRNA vaccines. Nat Reviews Methods Primers. 2023;3(1):63.</cite> [<a href="https://doi.org/10.1038/s43586-023-00246-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12312698/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40747084/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20S,%20Huang%20X,%20Xue%20Y,%20%C3%81lvarez-Benedicto%20E,%20Shi%20Y,%20Chen%20W,%20Koo%20S,%20Siegwart%20DJ,%20Dong%20Y,%20Tao%20W.%20Nanotechnology-based%20mRNA%20vaccines.%20Nat%20Reviews%20Methods%20Primers.%202023;3(1):63." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>No datasets were generated or analysed during the current study.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Cancer Cell International are provided here courtesy of <strong>BMC</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1186/s12935-025-03938-0"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/12935_2025_Article_3938.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (2.1 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12374352/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12374352/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12374352%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374352/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12374352/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12374352/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40849468/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12374352/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40849468/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12374352/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12374352/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="3ojAxNnwVesIzUCZfy9bJxvcIo6bq8OJSLVj4KhDbbEhbSNBR3fVA290OnaUjeP2">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
